Methods and compositions for synthesis of long chain polyunsaturated fatty acids

ABSTRACT

The present invention relates to fatty acid desaturases able to catalyze the conversion of oleic acid to linoleic acid, linoleic acid to gamma-linolenic acid, or of alpha-linolenic acid to stearidonic acid. Nucleic acid sequences encoding desaturases, nucleic acid sequences which hybridize thereto, DNA constructs comprising a desaturase gene, and recombinant host microorganism or animal expressing increased levels of a desaturase are described. Methods for desaturating a fatty acid and for producing a desaturated fatty acid by expressing increased levels of a desaturase are disclosed. Fatty acids, and oils containing them, which have been desaturated by a desaturase produced by recombinant host microorganisms or animals are provided. Pharmaceutical compositions, infant formulas or dietary supplements containing fatty acids which have been desaturated by a desaturase produced by a recombinant host microorganism or animal also are described.

This is a divisional of application Ser. No. 08/834,655, filed Apr. 11, 1997.

FIELD OF THE INVENTION

This invention relates to modulating levels of enzymes and/or enzyme components relating to production of long chain poly-unsaturated fatty acids (PUFAs) in a microorganism or animal. The invention is exemplified by the production of gamma-linolenic acid and stearidonic acid in yeast.

BACKGROUND

Two main families of poly-unsaturated fatty acids (PUFAs) are the ω3 fatty acids, exemplified by eicosapentaenoic acid (EPA), and the ω6 fatty acids, exemplified by arachidonic acid (ARA). PUFAs are important components of the plasma membrane of the cell, where they may be found in such forms as phospholipids and triglycerides. PUFAs are necessary for proper development, particularly in the developing infant brain, and for tissue formation and repair. PUFAs also serve as precursors to other molecules of importance in human beings and animals, including the prostacyclins, eicosanoids, leukotrienes and prostaglandins. Four major long chain PUFAs of importance include docosahexaenoic acid (DHA) and EPA, which are primarily found in different types of fish oil, gamma-linolenic acid (GLA), which is found in the seeds of a number of plants, including evening primrose (Oenothera biennis), borage (Borago officinalis) and black currants (Ribes nigrum), and stearidonic acid (SDA), which is found in marine oils and plant seeds. Both GLA and another important long chain PUFA, arachidonic acid (ARA), are found in filamentous fungi. ARA can be purified from animal tissues including liver and adrenal gland. GLA, ARA, EPA and SDA are themselves, or are dietary precursors to, important long chain fatty acids involved in prostaglandin synthesis, in treatment of heart disease, and in development of brain tissue.

Several disorders respond to treatment with fatty acids. Supplementation with PUFAs has been shown to reduce the rate of restenosis after angioplasty. Fish oil supplements have been shown to improve symptoms of inflammation and rheumatoid arthritis, and PUFAs have been suggested as treatments for asthma and psoriasis. Evidence indicates that PUFAs may be involved in calcium metabolism, suggesting that PUFAs may be useful in the treatment or prevention of osteoporosis and of kidney or urinary tract stones.

PUFAs can be used in the treatment of cancer. Malignant cells have been shown to have altered fatty acid compositions; addition of fatty acids has been shown to slow their growth and cause cell death, and to increase their susceptibility to chemotherapeutic agents. GLA has been shown to cause reexpression on cancer cells of the E-cadherin cellular adhesion molecules, loss of which is associated with aggressive metastasis. Clinical testing of intravenous administration of the water soluble lithium salt of GLA to pancreatic cancer patients produced statistically significant increases in their survival. PUFA supplementation may also be useful for treating cachexia associated with cancer.

PUFAs also can be used to treat diabetes (U.S. Pat. No. 4,826,877; Horrobin et al., Am. J. Clin. Nutr. Vol. 57 (Suppl.), 732S-737S). Altered fatty acid metabolism and composition has been demonstrated in diabetic animals. These alterations have been suggested to be involved in some of the long-term complications resulting from diabetes, including retinopathy, neuropathy, nephropathy and reproductive system damage. Primrose oil, which contains GLA, has been shown to prevent and reverse diabetic nerve damage.

Essential fatty acid deficiency has been suggested as being involved in eczema, and studies have shown beneficial effects on eczema from treatment with GLA. GLA has also been shown to reduce increases in blood pressure associated with stress, and to improve performance on arithmetic tests. GLA and DGLA have been shown to inhibit platelet aggregation, cause vasodilation, lower cholesterol levels and inhibit proliferation of vessel wall smooth muscle and fibrous tissue (Brenner et al., Adv. Exp. Med. Biol. Vol. 83, p. 85-101, 1976). Administration of GLA or DGLA, alone or in combination with EPA, has been shown to reduce or prevent gastrointestinal bleeding and other side effects caused by non-steroidal anti-inflammatory drugs (U.S. Pat. No. 4,666,701). GLA and DGLA have also been shown to prevent or treat endometriosis and premenstrual syndrome (U.S. Pat. No. 4,758,592) and to treat myalgic encephalomyelitis and chronic fatigue after viral infections (U.S. Pat. No. 5,116,871).

For DHA, a number of sources exist for commercial production including a variety of marine organisms, oils obtained from cold water marine fish, and egg yolk fractions. For ARA, microorganisms including the genera Mortierella, Entomophthora, Phytium and Porphyridium can be used for commercial production. Commercial sources of SDA include the genera Trichodesma and Echium. Commercial sources of GLA include evening primrose, black currants and borage. However, there are several disadvantages associated with commercial production of PUFAs from natural sources. Natural sources of PUFAs, such as animals and plants, tend to have highly heterogeneous oil compositions. The oils obtained from these sources therefore can require extensive purification to separate out one or more desired PUFAs or to produce an oil which is enriched in one or more PUFA. Natural sources also are subject to uncontrollable fluctuations in availability. Fish stocks may undergo natural variation or may be depleted by overfishing. Fish oils have unpleasant tastes and odors, which may be impossible to economically separate from the desired product, and can render such products unacceptable as food supplements. Animal oils, and particularly fish oils, can accumulate environmental pollutants. Weather and disease can cause fluctuation in yields from both fish and plant sources. Cropland available for production of alternate oil-producing crops is subject to competition from the steady expansion of human populations and the associated increased need for food production on the remaining arable land. Crops which do produce PUFAs, such as borage, have not been adapted to commercial growth and may not perform well in monoculture. Growth of such crops is thus not economically competitive where more profitable and better established crops can be grown. Large scale fermentation of organisms such as Mortierella is also expensive. Natural animal tissues contain low amounts of ARA and are difficult to process. Microorganisms such as Porphyridium and Mortierella are difficult to cultivate on a commercial scale.

Dietary supplements and pharmaceutical formulations containing PUFAs can retain the disadvantages of the PUFA source. Supplements such as fish oil capsules can contain low levels of the particular desired component and thus require large dosages. High dosages result in ingestion of high levels of undesired components, including contaminants. Unpleasant tastes and odors of the supplements can make such regimens undesirable, and may inhibit compliance by the patient. Care must be taken in providing fatty acid supplements, as overaddition may result in suppression of endogenous biosynthetic pathways and lead to competition with other necessary fatty acids in various lipid fractions in vivo, leading to undesirable results. For example, Eskimos having a diet high in ω3 fatty acids have an increased tendency to bleed (U.S. Pat. No. 4,874,603).

A number of enzymes are involved in PUFA biosynthesis. Linoleic acid (LA, 18:2 Δ⁹, 12) is produced from oleic acid (18:1 Δ⁹) by a Δ12-desaturase. GLA (18:3 Δ⁶, 9, 12) is produced from linoleic acid (LA, 18:2 Δ⁹, 12) by a Δ6-desaturase. ARA (20:4 Δ⁵, 8, 11, 14) production from dihomo-gamma-linolenic acid (DGLA, 20:3 Δ⁸, 11, 14) is catalyzed by a Δ5-desaturase. However, animals cannot desaturate beyond the Δ⁹ position and therefore cannot convert oleic acid (18:1 Δ⁹) into linoleic acid (18:2 Δ⁹, 12). Likewise, α-linolenic acid (ALA, 18:3 Δ⁹, 12, 15) cannot be synthesize by mammals. Other eukaryotes, including fungi and plants, have enzymes which desaturate at positions Δ¹² and Δ⁵. The major poly-unsaturated fatty acids of animals therefore are either derived from diet and/or from desaturation and elongation of linoleic acid (18:2 Δ⁹, 12) or ∝-linolenic acid (18:3 Δ⁹, 12, 15). Therefore it is of interest to obtain genetic material involved in PUFA biosynthesis from species that naturally produce these fatty acids and to express the isolated material in a microbial or animal system which can be manipulated to provide production of commercial quantities of one or more PUFAs. Thus there is a need for fatty acid desaturases, genes encoding them, and recombinant methods of producing them. A need further exists for oils containing higher relative proportions of and/or enriched in specific PUFAs. A need also exists for reliable economical methods of producing specific PUFAs.

RELEVANT LITERATURE

Production of gamma-linolenic acid by a Δ6-desaturase is described in U.S. Pat. No. 5,552,306. Production of 8, 11-eicosadienoic acid using Mortierella alpina is disclosed in U.S. Pat. No. 5,376,541. Production of docosahexaenoic acid by dinoflagellates is described in U.S. Pat. No. 5,407,957. Cloning of a Δ6-palmitoyl-acyl carrier protein desaturase is described in PCT publication WO 96/13591 and U.S. Pat. No. 5,614,400. Cloning of a Δ6-desaturase from borage is described in PCT publication WO 96/21022. Cloning of Δ9-desaturases is described in the published patent applications PCT WO 91/13972, EP 0 550 162 A1, EP 0 561 569 A2, EP 0 644 263 A2, and EP 0 736 598 A1, and in U.S. Pat. No. 5,057,419. Cloning of Δ12-desaturases from various organisms is described in PCT publication WO 94/11516 and U.S. Pat. No. 5,443,974. Cloning of Δ15-desaturases from various organisms is described in PCT publication WO 93/11245. All publications and U.S. patents or applications referred to herein are hereby incorporated in their entirety by reference.

SUMMARY OF THE INVENTION

Novel compositions and methods are provided for preparation of poly-unsaturated long chain fatty acids. The compositions include nucleic acid encoding a Δ6- and Δ12-desaturase and/or polypeptides having Δ6- and/or Δ12-desaturase activity, the polypeptides, and probes isolating and detecting the same. The methods involve growing a host microorganism or animal expressing an introduced gene or genes encoding at least one desaturase, particularly a Δ6-, Δ9-, Δ12- or Δ15-desaturase. The methods also involve the use of antisense constructs or gene disruptions to decrease or eliminate the expression level of undesired desaturases. Regulation of expression of the desaturase polypeptide(s) provides for a relative increase in desired desaturated PUFAs as a result of altered concentrations of enzymes and substrates involved in PUFA biosynthesis. The invention finds use, for example, in the large scale production of GLA, DGLA, ARA, EPA, DUA and SDA.

In a preferred embodiment of the invention, an isolated nucleic acid comprising: a nucleotide sequence depicted in FIGS. 3A-E (SEQ ID NO: 1) or FIGS. 5A-D (SEQ ID NO: 3), a polypeptide encoded by a nucleotide sequence according FIGS. 3A-E (SEQ ID NO: 1) or FIGS. 5A-D (SEQ ID NO: 3), and a purified or isolated polypeptide comprising an amino acid sequence depicted in FIGS. 3A-E (SEQ ID NO: 2) or FIGS. 5A-D (SEQ ID NO: 4). In another embodiment of the invention, provided is an isolated nucleic acid encoding a polypeptide having an amino acid sequence depicted in FIGS. 3A-E (SEQ ID NO: 2) or FIGS. 5A-D (SEQ ID NO: 4). Also provided is an isolated nucleic acid comprising a nucleotide sequence which encodes a polypeptide which desaturates a fatty acid molecule at carbon 6 or 12, wherein said nucleotide sequence has an average A/T content of less than about 60%. In a preferred embodiment, the isolated nucleic acid is derived from a fungus, such as a fungus of the genus Mortierella. More preferred is a fungus of the species Mortierella alpina.

In another preferred embodiment of the invention, an isolated nucleic acid is provided wherein the nucleotide sequence of the nucleic acid is depicted in FIGS. 3A-E (SEQ ID NO: 1) or FIGS. 5A-D (SEQ ID NO: 3). The invention also provides an isolated or purified polypeptide which desaturates a fatty acid molecule at carbon 6 or 12, wherein the polypeptide is a eukaryotic polypeptide or is derived from a eukaryotic polypeptide, where a preferred eukaryotic polypeptide is derived from a fungus.

The present invention further includes a nucleic acid sequence which hybridizes to FIGS. 3A-E (SEQ ID NO: 1) or FIGS. 5A-D (SEQ ID NO: 3). Preferred is an isolated nucleic acid having a nucleotide sequence with at least about 50% homology to FIGS. 3A-E (SEQ ID NO: 1) or FIGS. 5A-D (SEQ ID NO: 3). The invention also includes an isolated nucleic acid having a nucleotide sequence with at least about 50% homology to FIGS. 3A-E (SEQ ID NO: 1) or FIGS. 5A-D (SEQ ID NO: 3). In a preferred embodiment, the nucleic acid of the invention includes a nucleotide sequence which encodes an amino acid sequence depicted in FIGS. 3A-D (SEQ ID NO: 2) which is selected from the group consisting of amino acid residues 50-53, 39-43, 172-176, 204-213, and 390-402.

Also provided by the present invention is a nucleic acid construct comprising a nucleotide sequence depicted in a FIGS. 3A-E (SEQ ID NO: 1) or FIGS. 5A-D (SEQ ID NO: 3) linked to a heterologous nucleic acid. In another embodiment, a nucleic acid construct is provided which comprises a nucleotide sequence depicted in a FIGS. 3A-E (SEQ ID NO: 1) or FIGS. 5A-D (SEQ ID NO: 3) operably associated with an expression control sequence functional in a host cell. The host cell is either eukaryotic or prokaryotic. Preferred eukaryotic host cells are those selected from the group consisting of a mammalian cell, an insect cell, a fungal cell, and an algae cell. Preferred mammalian cells include an avian cell, a preferred fungal cell includes a yeast cell, and a preferred algae cell is a marine algae cell. Preferred prokaryotic cells include those selected from the group consisting of a bacteria, a cyanobacteria, cells which contain a bacteriophage, and/or a virus. The DNA sequence of the recombinant host cell preferably contains a promoter which is functional in the host cell, which promoter is preferably inducible. In a more preferred embodiment, the microbial cell is a fungal cell of the genus Mortierella, with a more preferred fungus is of the species Mortierella alpina.

In addition, the present invention provides a nucleic acid construct comprising a nucleotide sequence which encodes a polypeptide comprising an amino acid sequence which corresponds to or is complementary to an amino acid sequence depicted in FIGS. 3A-E (SEQ ID NO: 2) or FIGS. 5A-D (SEQ ID NO: 4), wherein the nucleic acid is operably associated with an expression control sequence functional in a microbial cell, wherein the nucleotide sequence encodes a functionally active polypeptide which desaturates a fatty acid molecule at carbon 5 or carbon 11 from the carboxyl end of a fatty acid molecule. Another embodiment of the present invention is a nucleic acid construct comprising a nucleotide sequence which encodes a functionally active Δ6-desaturase having an amino acid sequence which corresponds to or is complementary to all of or a portion of an amino acid sequence depicted in a FIGS. 3A-E (SEQ ID NO: 2), wherein the nucleotide sequence is operably associated with a transcription control sequence functional in a host cell.

Yet another embodiment of the present invention is a nucleic acid construct comprising a nucleotide sequence which encodes a functionally active Δ12-desaturase having an amino acid sequence which corresponds to or is complementary to all of or a portion of an amino acid sequence depicted in a FIGS. 5A-D (SEQ ID NO: 4), wherein the nucleotide sequence is operably associated with a transcription control sequence functional in a host cell. The host cell, is either a eukaryotic or prokaryotic host cell. Preferred eukaryotic host cells are those selected from the group consisting of a mammalian cell, an insect cell, a fungal cell, and an algae cell. Preferred mammalian cells include an avian cell, a preferred fungal cell includes a yeast cell, and a preferred algae cell is a marine algae cell. Preferred prokaryotic cells include those selected from the group consisting of a bacteria, a cyanobacteria, cells which contain a bacteriophage, and/or a virus. The DNA sequence of the recombinant host cell preferably contains a promoter which is functional in the host cell and which preferably is inducible. A preferred recombinant host cell is a microbial cell such as a yeast cell, such as a Saccharomyces cell.

The present invention also provides a recombinant microbial cell comprising at least one copy of a nucleic acid which encodes a functionally active Mortierella alpina fatty acid desaturase having an amino acid sequence as depicted in FIGS. 3A-E (SEQ ID NO: 2), wherein the cell or a parent of the cell was transformed with a vector comprising said DNA sequence, and wherein the DNA sequence is operably associated with an expression control sequence. In another preferred embodiment, the microbial cell according to the invention includes an expression control sequence which is endogenous to the microbial cell.

Also provided by the present invention is a method for production of GLA in a host cell, where the method comprises growing a host culture having a plurality of host cells which contain one or more nucleic acids encoding a polypeptide which converts LA to GLA, wherein said one or more nucleic acids is operably associated with an expression control sequence, under conditions whereby said one or more nucleic acids are expressed, whereby GLA is produced in the host cell. In several preferred embodiments of the methods, the polypeptide employed in the method is a functionally active enzyme which desaturates a fatty acid molecule at carbon 6 from the carboxyl end of a fatty acid molecule; the said one or more nucleic acids is derived from a Mortierella alpina; the substrate for the polypeptide is exogenously supplied; the host cells are microbial cells; the microbial cells are yeast cells, such as Saccharomyces cells; and the growing conditions are inducible.

In another embodiment of the invention, a recombinant yeast cell is provided which converts 18:1 fatty acids to 18:2 fatty acids, 18:2 fatty acids to 18:3 fatty acids and/or 18:3 fatty acids to 18:4 fatty acids.

Also provided is an oil comprising one or more PUFA, wherein the amount of said one or more PUFAs is approximately 0.3-30% arachidonic acid (ARA), approximately 0.2-30% dihomo-γ-linoleic acid (DGLA), and approximately 0.2-30% γ-linoleic acid (GLA). A preferred oil of the invention is one in which the ratio of ARA:DGLA:GLA is approximately 1.0:19.0:30 to 6.0:1.0:0.2. Another preferred embodiment of the invention is a pharmaceutical composition comprising the oils in a pharmaceutically acceptable carrier. Further provided is a nutritional composition comprising the oils of the invention. The nutritional compositions of the invention preferably are administered to a mammalian host parenterally or internally. A preferred composition of the invention for internal consumption is an infant formula. In a preferred embodiment, the nutritional compositions of the invention are in a liquid form or a solid form, and can be formulated in or as a dietary supplement, and the oils provided in encapsulated form. The oils of the invention can be free of particular components of other oils and can be derived from a microbial cell, such as a yeast cell.

The present invention further provides a method for desaturating a fatty acid. In a preferred embodiment the method comprises culturing a recombinant microbial cell according to the invention under conditions suitable for expression of a polypeptide encoded by said nucleic acid, wherein the host cell further comprises a fatty acid substrate of said polypeptide. Also provided is a fatty acid desaturated by such a method, and an oil composition comprising a fatty acid produced according to the methods of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows possible pathways for the synthesis of arachidonic acid (20:4 Δ⁵, 8, 11, 14) and stearidonic acid (18:4 Δ⁶, 9, 12, 15) from palmitic acid (C₁₆) from a variety of organisms, including algae, Mortierella and humans. These PUFAs can serve as precursors to other molecules important for humans and other animals, including prostacyclins, leukotrienes, and prostaglandins, some of which are shown.

FIG. 2 shows possible pathways for production of PUFAs in addition to ARA, including EPA and DHA, again compiled from a variety of organisms.

FIGS. 3A-E shows the DNA sequence of the Mortierella alpina Δ6-desaturase and the deduced amino acid sequence:

FIGS. 3A-E (SEQ ID NO 1 DELTA 6 DESATURASE cDNA)

FIGS. 3A-E (SEQ ID NO 2 DELTA 6 DESATURASE AMINO ACID)

FIG. 4 shows an alignment of a portion of the Mortierella alpina Δ6-desaturase amino acid sequence, Ma524 (SEQ ID NO:5), with other related sequences: ATTS4723 (SEQ ID NO:6), 12-5 (SEQ ID NO:7), T42806 (SEQ ID NO:8), W28140 (SEQ ID NO:9), R05219 (SEQ ID NO:10), W53753 (SEQ ID NO:11).

FIGS. 5A-D shows the DNA sequence of the Mortierella alpina Δ12-desaturase and the deduced amino acid sequence:

FIGS. 5A-D (SEQ ID NO 3 DELTA 12 DESATURASE cDNA)

FIGS. 5A-D (SEQ ID NO 4 DELTA 12 DESATURASE AMINO ACID).

FIGS. 6A and 6B show the effect of different expression constructs on expression of GLA in yeast.

FIGS. 7A and 7B show the effect of host strain on GLA production.

FIGS. 8A and 8B show the effect of temperature on GLA production in S. cerevisiae strain SC334.

BRIEF DESCRIPTION OF THE SEQUENCE LISTINGS

SEQ ID NO:1 shows the DNA sequence of the Mortierella alpina Δ6-desaturase.

SEQ ID NO:2 shows the protein sequence of the Mortierella alpina Δ6-desaturase.

SEQ ID NO:3 shows the DNA sequence of the Mortierella alpina Δ12-desaturase.

SEQ ID NO:4 shows the protein sequence of the Mortierella alpina Δ12-desaturase.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

In accordance with the subject invention, novel DNA sequences, DNA constructs, methods and compositions are provided which permit modification of the poly-unsaturated long chain fatty acid content of, for example, microbial cells or animals. Host cells are manipulated to express a sense or antisense transcript of a DNA encoding a polypeptide(s) which catalyzes the desaturation of a fatty acid. The substrate(s) for the expressed enzyme may be produced by the host cell or may be exogenously supplied. To achieve expression, the transformed DNA is operably associated with transcriptional and translational initiation and termination regulatory regions that are functional in the host cell. Constructs comprising the gene to be expressed can provide for integration into the genome of the host cell or can autonomously replicate in the host cell. For production of linoleic acid (LA), the expression cassettes generally used include a cassette which provides for Δ12-desaturase activity, particularly in a host cell which produces or can take up oleic acid (U.S. Pat. No. 5,443,974). Production of LA also can be increased by providing an expression cassette for a Δ9-desaturase where that enzymatic activity is limiting. For production of ALA, the expression cassettes generally used include a cassette which provides for Δ15- or ω3-desaturase activity, particularly in a host cell which produces or can take up LA. For production of GLA or SDA, the expression cassettes generally used include a cassette which provides for Δ6-desaturase activity, particularly in a host cell which produces or can take up LA or ALA, respectively. Production of ω6-type unsaturated fatty acids, such as LA or GLA, is favored in a host microorganism or animal which is incapable of producing ALA. The host ALA production can be removed, reduced and/or inhibited by inhibiting the activity of a Δ15- or ω3-type desaturase (see FIG. 2). This can be accomplished by standard selection, providing an expression cassette for an antisense Δ15 or ω3 transcript, by disrupting a target Δ15- or ω3-desaturase gene through insertion, deletion, substitution of part or all of the target gene, or by adding an inhibitor of Δ15- or ω3-desaturase. Similarly, production of LA or ALA is favored in a microorganism or animal having Δ6-desaturase activity by providing an expression cassette for an antisense Δ6 transcript, by disrupting a Δ6-desaturase gene, or by use of a Δ6-desaturase inhibitor.

Microbial production of fatty acids has several advantages over purification from natural sources such as fish or plants. Many microbes are known with greatly simplified oil compositions compared with those of higher organisms, making purification of desired components easier. Microbial production is not subject to fluctuations caused by external variables such as weather and food supply. Microbially produced oil is substantially free of contamination by environmental pollutants. Additionally, microbes can provide PUFAs in particular forms which may have specific uses. For example, Spirulina can provide PUFAs predominantly at the first and third positions of triglycerides; digestion by pancreatic lipases preferentially releases fatty acids from these positions. Following human or animal ingestion of triglycerides derived from Spirulina, these PUFAs are released by pancreatic lipases as free fatty acids and thus are directly available, for example, for infant brain development. Additionally, microbial oil production can be manipulated by controlling culture conditions, notably by providing particular substrates for microbially expressed enzymes, or by addition of compounds which suppress undesired biochemical pathways. In addition to these advantages, production of fatty acids from recombinant microbes provides the ability to alter the naturally occurring microbial fatty acid profile by providing new synthetic pathways in the host or by suppressing undesired pathways, thereby increasing levels of desired PUFAs, or conjugated forms thereof, and decreasing levels of undesired PUFAs.

Production of fatty acids in animals also presents several advantages. Expression of desaturase genes in animals can produce greatly increased levels of desired PUFAs in animal tissues, making recovery from those tissues more economical. For example, where the desired PUFAs are expressed in the breast milk of animals, methods of isolating PUFAs from animal milk are well established. In addition to providing a source for purification of desired PUFAs, animal breast milk can be manipulated through expression of desaturase genes, either alone or in combination with other human genes, to provide animal milks substantially similar to human breast milk during the different stages of infant development. Humanized animal milks could serve as infant formulas where human nursing is impossible or undesired, or in cases of malnourishment or disease.

Depending upon the host cell, the availability of substrate, and the desired end product(s), several polypeptides, particularly desaturases, are of interest. By "desaturase" is intended a polypeptide which can desaturate one or more fatty acids to produce a mono- or poly-unsaturated fatty acid or precursor thereof of interest. Of particular interest are polypeptides which can catalyze the conversion of stearic acid to oleic acid, of oleic acid to LA, of LA to ALA, of LA to GLA, or of ALA to SDA, which includes enzymes which desaturate at the Δ9, Δ12, ω6, Δ15, ω3 or Δ6 positions. By "polypeptide" is meant any chain of amino acids, regardless of length or post-translational modification, for example, glycosylation or phosphorylation. Considerations for choosing a specific polypeptide having desaturase activity include the pH optimum of the polypeptide, whether the polypeptide is a rate limiting enzyme or a component thereof, whether the desaturase used is essential for synthesis of a desired poly-unsaturated fatty acid, and/or co-factors required by the polypeptide. The expressed polypeptide preferably has parameters compatible with the biochemical environment of its location in the host cell. For example, the polypeptide may have to compete for substrate with other enzymes in the host cell. Analyses of the K_(m) and specific activity of the polypeptide in question therefore are considered in determining the suitability of a given polypeptide for modifying PUFA production in a given host cell. The polypeptide used in a particular situation is one which can function under the conditions present in the intended host cell but otherwise can be any polypeptide having desaturase activity which has the desired characteristic of being capable of modifying the relative production of a desired PUFA.

For production of linoleic acid from oleic acid, the DNA sequence used encodes a polypeptide having Δ12-desaturase activity. For production of GLA from linoleic acid, the DNA sequence used encodes a polypeptide having Δ6-desaturase activity. In particular instances, expression of Δ6-desaturase activity can be coupled with expression of Δ12-desaturase activity and the host cell can optionally be depleted of any Δ15-desaturase activity present, for example by providing a transcription cassette for production of antisense sequences to the Δ15-desaturase transcription product, by disrupting the Δ15-desaturase gene, or by using a host cell which naturally has, or has been mutated to have, low Δ15-desaturase activity. Inhibition of undesired desaturase pathways also can be accomplished through the use of specific desaturase inhibitors such as those described in U.S. Pat. No. 4,778,630. Also, a host cell for Δ6-desaturase expression may have, or have been mutated to have, high Δ12-desaturase activity. The choice of combination of cassettes used depends in part on the PUFA profile and/or desaturase profile of the host cell. Where the host cell expresses Δ12-desaturase activity and lacks or is depleted in Δ15-desaturase activity, overexpression of Δ6-desaturase alone generally is sufficient to provide for enhanced GLA production. Where the host cell expresses Δ9-desaturase activity, expression of a Δ12- and a Δ6-desaturase can provide for enhanced GLA production. When Δ9-desaturase activity is absent or limiting, an expression cassette for Δ9-desaturase can be used. A scheme for the synthesis of arachidonic acid (20:4 Δ⁵, 8, 11, 14) from stearic acid (18:0) is shown in FIG. 2. A key enzyme in this pathway is a Δ6-desaturase which converts the linoleic acid into γ-linolenic acid. Conversion of α-linolenic acid (ALA) to stearidonic acid by a Δ6-desaturase also is shown.

As a source of polypeptides having desaturase activity and oligonucleotides encoding such polypeptides are organisms which produce a desired poly-unsaturated fatty acid. As an example, microorganisms having an ability to produce GLA or ARA can be used as a source of Δ6- or Δ12-desaturase activity. Such microorganisms include, for example, those belonging to the genera Mortierella, Conidiobolus, Pythium, Phytophathora, Penicillium, Porphyridium, Coidosporium, Mucor, Fusarium, Aspergillus, Rhodotorula, and Entomophthora. Within the genus Porphyridium, of particular interest is Porphyridium cruentum. Within the genus Mortierella, of particular interest are Mortierella elongata, Mortierella exigua, Mortierella hygrophila, Mortierella ramanniana, var. angulispora, and Mortierella alpina. Within the genus Mucor, of particular interest are Mucor circinelloides and Mucor javanicus.

DNAs encoding desired desaturases can be identified in a variety of ways. As an example, a source of the desired desaturase, for example genomic or cDNA libraries from Mortierella, is screened with detectable enzymatically- or chemically-synthesized probes, which can be made from DNA, RNA, or non-naturally occurring nucleotides, or mixtures thereof. Probes may be enzymatically synthesized from DNAs of known desaturases for normal or reduced-stringency hybridization methods. Oligonucleotide probes also can be used to screen sources and can be based on sequences of known desaturases, including sequences conserved among known desaturases, or on peptide sequences obtained from the desired purified protein. Oligonucleotide probes based on amino acid sequences can be degenerate to encompass the degeneracy of the genetic code, or can be biased in favor of the preferred codons of the source organism. Oligonucleotides also can be used as primers for PCR from reverse transcribed mRNA from a known or suspected source; the PCR product can be the full length cDNA or can be used to generate a probe to obtain the desired full length cDNA. Alternatively, a desired protein can be entirely sequenced and total synthesis of a DNA encoding that polypeptide performed.

Once the desired genomic or cDNA has been isolated, it can be sequenced by known methods. It is recognized in the art that such methods are subject to errors, such that multiple sequencing of the same region is routine and is still expected to lead to measurable rates of mistakes in the resulting deduced sequence, particularly in regions having repeated domains, extensive secondary structure, or unusual base compositions, such as regions with high GC base content. When discrepancies arise, resequencing can be done and can employ special methods. Special methods can include altering sequencing conditions by using: different temperatures; different enzymes; proteins which alter the ability of oligonucleotides to form higher order structures; altered nucleotides such as ITP or methylated dGTP; different gel compositions, for example adding formamide; different primers or primers located at different distances from the problem region; or different templates such as single stranded DNAs. Sequencing of mRNA also can be employed.

For the most part, some or all of the coding sequence for the polypeptide having desaturase activity is from a natural source. In some situations, however, it is desirable to modify all or a portion of the codons, for example, to enhance expression, by employing host preferred codons. Host preferred codons can be determined from the codons of highest frequency in the proteins expressed in the largest amount in a particular host species of interest. Thus, the coding sequence for a polypeptide having desaturase activity can be synthesized in whole or in part. All or portions of the DNA also can be synthesized to remove any destabilizing sequences or regions of secondary structure which would be present in the transcribed mRNA. All or portions of the DNA also can be synthesized to alter the base composition to one more preferable in the desired host cell. Methods for synthesizing sequences and bringing sequences together are well established in the literature. In vitro mutagenesis and selection, site-directed mutagenesis, or other means can be employed to obtain mutations of naturally occurring desaturase genes to produce a polypeptide having desaturase activity in vivo with more desirable physical and kinetic parameters for function in the host cell, such as a longer half-life or a higher rate of production of a desired polyunsaturated fatty acid.

Of particular interest is the Mortierella alpina Δ6-desaturase, which has 457 amino acids and a predicted molecular weight of 51.8 kD; the amino acid sequence is shown in FIG. 3. The gene encoding the Mortierella alpina Δ6-desaturase can be expressed in transgenic microorganisms or animals to effect greater synthesis of GLA from linoleic acid or of stearidonic acid from ALA. Other DNAs which are substantially identical to the Mortierella alpina Δ6-desaturase DNA, or which encode polypeptides which are substantially identical to the Mortierella alpina Δ6-desaturase polypeptide, also can be used. By substantially identical is intended an amino acid sequence or nucleic acid sequence exhibiting in order of increasing preference at least 60%, 80%, 90% or 95% homology to the Mortierella alpina Δ6-desaturase amino acid sequence or nucleic acid sequence encoding the amino acid sequence. For polypeptides, the length of comparison sequences generally is at least 16 amino acids, preferably at least 20 amino acids, or most preferably 35 amino acids. For nucleic acids, the length of comparison sequences generally is at least 50 nucleotides, preferably at least 60 nucleotides, and more preferably at least 75 nucleotides, and most preferably, 110 nucleotides. Homology typically is measured using sequence analysis software, for example, the Sequence Analysis software package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, MEGAlign (DNAStar, Inc., 1228 S. Park St., Madison, Wis. 53715), and MacVector (Oxford Molecular Group, 2105 S. Bascom Avenue, Suite 200, Campbell, Calif. 95008). Such software matches similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine and leucine; aspartic acid, glutamic acid, asparagine, and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine. Substitutions may also be made on the basis of conserved hydrophobicity or hydrophilicity (Kyte and Doolittle, J. Mol. Biol. 157: 105-132, 1982), or on the basis of the ability to assume similar polypeptide secondary structure (Chou and Fasman, Adv. Enzymol. 47: 45-148, 1978).

Also of interest is the Mortierella alpina Δ12-desaturase, the nucleotide and amino acid sequence of which is shown in FIG. 5. The gene encoding the Mortierella alpina Δ12-desaturase can be expressed in transgenic microorganisms or animals to effect greater synthesis of LA from oleic acid. Other DNAs which are substantially identical to the Mortierella alpina Δ12-desaturase DNA, or which encode polypeptides which are substantially identical to the Mortierella alpina Δ12-desaturase polypeptide, also can be used.

Encompassed by the present invention are related desaturases from the same or other organisms. Such related desaturases include variants of the disclosed Δ6- or Δ12-desaturase naturally occurring within the same or different species of Mortierella, as well as homologues of the disclosed Δ6- or Δ12-desaturase from other species. Also included are desaturases which, although not substantially identical to the Mortierella alpina Δ6- or Δ12-desaturase, desaturate a fatty acid molecule at carbon 6 or 12, respectively, from the carboxyl end of a fatty acid molecule, or at carbon 12 or 6, respectively from the terminal methyl carbon in an 18 carbon fatty acid molecule. Related desaturases can be identified by their ability to function substantially the same as the disclosed desaturases; that is, are still able to effectively convert LA to GLA, ALA to SDA or oleic acid to LA. Related desaturases also can be identified by screening sequence databases for sequences homologous to the disclosed desaturases, by hybridization of a probe based on the disclosed desaturases to a library constructed from the source organism, or by RT-PCR using mRNA from the source organism and primers based on the disclosed desaturases.

The regions of a desaturase polypeptide important for desaturase activity can be determined through routine mutagenesis, expression of the resulting mutant polypeptides and determination of their activities. Mutants may include deletions, insertions and point mutations, or combinations thereof. A typical functional analysis begins with deletion mutagenesis to determine the N- and C-terminal limits of the protein necessary for function, and then internal deletions, insertions or point mutants are made to further determine regions necessary for function. Other techniques such as cassette mutagenesis or total synthesis also can be used. Deletion mutagenesis is accomplished, for example, by using exonucleases to sequentially remove the 5' or 3' coding regions. Kits are available for such techniques. After deletion, the coding region is completed by ligating oligonucleotides containing start or stop codons to the deleted coding region after 5' or 3' deletion, respectively. Alternatively, oligonucleotides encoding start or stop codons are inserted into the coding region by a variety of methods including site-directed mutagenesis, mutagenic PCR or by ligation onto DNA digested at existing restriction sites. Internal deletions can similarly be made through a variety of methods including the use of existing restriction sites in the DNA, by use of mutagenic primers via site directed mutagenesis or mutagenic PCR. Insertions are made through methods such as linker-scanning mutagenesis, site-directed mutagenesis or mutagenic PCR. Point mutations are made through techniques such as site-directed mutagenesis or mutagenic PCR.

Chemical mutagenesis also can be used for identifying regions of a desaturase polypeptide important for activity. A mutated construct is expressed, and the ability of the resulting altered protein to function as a desaturase is assayed. Such structure-function analysis can determine which regions may be deleted, which regions tolerate insertions, and which point mutations allow the mutant protein to function in substantially the same way as the native desaturase. All such mutant proteins and nucleotide sequences encoding them are within the scope of the present invention.

Once the DNA encoding a desaturase polypeptide has been obtained, it is placed in a vector capable of replication in a host cell, or is propagated in vitro by means of techniques such as PCR or long PCR. Replicating vectors can include plasmids, phage, viruses, cosmids and the like. Desirable vectors include those useful for mutagenesis of the gene of interest or for expression of the gene of interest in host cells. The technique of long PCR has made in vitro propagation of large constructs possible, so that modifications to the gene of interest, such as mutagenesis or addition of expression signals, and propagation of the resulting constructs can occur entirely in vitro without the use of a replicating vector or a host cell.

For expression of a desaturase polypeptide, functional transcriptional and translational initiation and termination regions are operably linked to the DNA encoding the desaturase polypeptide. Expression of the polypeptide coding region can take place in vitro or in a host cell. Transcriptional and translational initiation and termination regions are derived from a variety of nonexclusive sources, including the DNA to be expressed, genes known or suspected to be capable of expression in the desired system, expression vectors, chemical synthesis, or from an endogenous locus in a host cell.

In vitro expression can be accomplished, for example, by placing the coding region for the desaturase polypeptide in an expression vector designed for in vitro use and adding rabbit reticulocyte lysate and cofactors; labeled amino acids can be incorporated if desired. Such in vitro expression vectors may provide some or all of the expression signals necessary in the system used. These methods are well known in the art and the components of the system are commercially available. The reaction mixture can then be assayed directly for the polypeptide, for example by determining its activity, or the synthesized polypeptide can be purified and then assayed.

Expression in a host cell can be accomplished in a transient or stable fashion. Transient expression can occur from introduced constructs which contain expression signals functional in the host cell, but which constructs do not replicate and rarely integrate in the host cell, or where the host cell is not proliferating. Transient expression also can be accomplished by inducing the activity of a regulatable promoter operably linked to the gene of interest, although such inducible systems frequently exhibit a low basal level of expression. Stable expression can be achieved by introduction of a construct that can integrate into the host genome or that autonomously replicates in the host cell. Stable expression of the gene of interest can be selected for through the use of a selectable marker located on or transfected with the expression construct, followed by selection for cells expressing the marker. When stable expression results from integration, integration of constructs can occur randomly within the host genome or can be targeted through the use of constructs containing regions of homology with the host genome sufficient to target recombination with the host locus. Where constructs are targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions can be provided by the endogenous locus.

When increased expression of the desaturase polypeptide in the source organism is desired, several methods can be employed. Additional genes encoding the desaturase polypeptide can be introduced into the host organism. Expression from the native desaturase locus also can be increased through homologous recombination, for example by inserting a stronger promoter into the host genome to cause increased expression, by removing destabilizing sequences from either the mRNA or the encoded protein by deleting that information from the host genome, or by adding stabilizing sequences to the mRNA (U.S. Pat. No. 4,910,141).

When it is desirable to express more than one different gene, appropriate regulatory regions and expression methods, introduced genes can be propagated in the host cell through use of replicating vectors or by integration into the host genome. Where two or more genes are expressed from separate replicating vectors, it is desirable that each vector has a different means of replication. Each introduced construct, whether integrated or not, should have a different means of selection and should lack homology to the other constructs to maintain stable expression and prevent reassortment of elements among constructs. Judicious choices of regulatory regions, selection means and method of propagation of the introduced construct can be experimentally determined so that all introduced genes are expressed at the necessary levels to provide for synthesis of the desired products.

As an example, where the host cell is a yeast, transcriptional and translational regions functional in yeast cells are provided, particularly from the host species. The transcriptional initiation regulatory regions can be obtained, for example from genes in the glycolytic pathway, such as alcohol dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase (GPD), phosphoglucoisomerase, phosphoglycerate kinase, etc. or regulatable genes such as acid phosphatase, lactase, metallothionein, glucoamylase, etc. Any one of a number of regulatory sequences can be used in a particular situation, depending upon whether constitutive or induced transcription is desired, the particular efficiency of the promoter in conjunction with the open-reading of interest, the ability to join a strong promoter with a control region from a different promoter which allows for inducible transcription, ease of construction, and the like. Of particular interest are promoters which are activated in the presence of galactose. Galactose-inducible promoters (GAL1, GAL7, and GAL10) have been extensively utilized for high level and regulated expression of protein in yeast (Lue et al., Mol. Cell. Biol. Vol. 7, p. 3446, 1987; Johnston, Microbiol. Rev. Vol. 51, p. 458, 1987). Transcription from the GAL promoters is activated by the GAL4 protein, which binds to the promoter region and activates transcription when galactose is present. In the absence of galactose, the antagonist GAL80 binds to GAL4 and prevents GAL4 from activating transcription. Addition of galactose prevents GAL80 from inhibiting activation by GAL4.

Nucleotide sequences surrounding the translational initiation codon ATG have been found to affect expression in yeast cells. If the desired polypeptide is poorly expressed in yeast, the nucleotide sequences of exogenous genes can be modified to include an efficient yeast translation initiation sequence to obtain optimal gene expression. For expression in Saccharomyces, this can be done by site-directed mutagenesis of an inefficiently expressed gene by fusing it in-frame to an endogenous Saccharomyces gene, preferably a highly expressed gene, such as the lactase gene.

The termination region can be derived from the 3' region of the gene from which the initiation region was obtained or from a different gene. A large number of termination regions are known to and have been found to be satisfactory in a variety of hosts from the same and different genera and species. The termination region usually is selected more as a matter of convenience rather than because of any particular property. Preferably, the termination region is derived from a yeast gene, particularly Saccharomyces, Schizosaccharomyces, Candida or Kluyveromyces. The 3' regions of two mammalian genes, γ interferon and α2 interferon, are also known to function in yeast.

Constructs comprising the gene of interest may be introduced into a host cell by standard techniques. These techniques include transformation, protoplast fusion, lipofection, transfection, transduction, conjugation, infection, bolistic impact, electroporation, microinjection, scraping, or any other method which introduces the gene of interest into the host cell. Methods of transformation which are used include lithium acetate transformation (Methods in Enzymology, Vol. 194, p. 186-187, 1991). For convenience, a host cell which has been manipulated by any method to take up a DNA sequence or construct will be referred to as "transformed" or "recombinant" herein.

The subject host will have at least have one copy of the expression construct and may have two or more, depending upon whether the gene is integrated into the genome, amplified, or is present on an extrachromosomal element having multiple copy numbers. Where the subject host is a yeast, four principal types of yeast plasmid vectors can be used: Yeast Integrating plasmids (YIps), Yeast Replicating plasmids (YRps), Yeast Centromere plasmids (YCps), and Yeast Episomal plasmids (YEps). YIps lack a yeast replication origin and must be propagated as integrated elements in the yeast genome. YRps have a chromosomally derived autonomously replicating sequence and are propagated as medium copy number (20 to 40), autonomously replicating, unstably segregating plasmids. YCps have both a replication origin and a centromere sequence and propagate as low copy number (10-20), autonomously replicating, stably segregating plasmids. YEps have an origin of replication from the yeast 2 μm plasmid and are propagated as high copy number, autonomously replicating, irregularly segregating plasmids. The presence of the plasmids in yeast can be ensured by maintaining selection for a marker on the plasmid. Of particular interest are the yeast vectors pYES2 (a YEp plasmid available from Invitrogen, confers uracil prototrophy and a GAL1 galactose-inducible promoter for expression), pRS425-pG1 (a YEp plasmid obtained from Dr. T. H. Chang, Ass. Professor of Molecular Genetics, Ohio State University, containing a constitutive GPD promoter and conferring leucine prototrophy), and pYX424 (a YEp plasmid having a constitutive TP1 promoter and conferring leucine prototrophy; Alber, T. and Kawasaki, G. (1982). J. Mol. & Appl. Genetics 1: 419).

The transformed host cell can be identified by selection for a marker contained on the introduced construct. Alternatively, a separate marker construct may be introduced with the desired construct, as many transformation techniques introduce many DNA molecules into host cells. Typically, transformed hosts are selected for their ability to grow on selective media. Selective media may incorporate an antibiotic or lack a factor necessary for growth of the untransformed host, such as a nutrient or growth factor. An introduced marker gene therefor may confer antibiotic resistance, or encode an essential growth factor or enzyme, and permit growth on selective media when expressed in the transformed host. Selection of a transformed host can also occur when the expressed marker protein can be detected, either directly or indirectly. The marker protein may be expressed alone or as a fusion to another protein. The marker protein can be detected by its enzymatic activity; for example β galactosidase can convert the substrate X-gal to a colored product, and luciferase can convert luciferin to a light-emitting product. The marker protein can be detected by its light-producing or modifying characteristics; for example, the green fluorescent protein of Aequorea victoria fluoresces when illuminated with blue light. Antibodies can be used to detect the marker protein or a molecular tag on, for example, a protein of interest. Cells expressing the marker protein or tag can be selected, for example, visually, or by techniques such as FACS or panning using antibodies. For selection of yeast transformants, any marker that functions in yeast may be used. Desirably, resistance to kanamycin and the amino glycoside G418 are of interest, as well as ability to grow on media lacking uracil, leucine, lysine or tryptophan.

Of particular interest is the Δ6- and Δ12-desaturase-mediated production of PUFAs in prokaryotic and eukaryotic host cells. Prokaryotic cells of interest include Eschericia, Bacillus, Lactobacillus, cyanobacteria and the like. Eukaryotic cells include mammalian cells such as those of lactating animals, avian cells such as of chickens, and other cells amenable to genetic manipulation including insect, fungal, and algae cells. The cells may be cultured or formed as part or all of a host organism including an animal. Viruses and bacteriophage also may be used with the cells in the production of PUFAs, particularly for gene transfer, cellular targeting and selection. In a preferred embodiment, the host is any microorganism or animal which produces and/or can assimilate exogenously supplied substrate(s) for a Δ6- and/or Δ12-desaturase, and preferably produces large amounts of one or more of the substrates. Examples of host animals include mice, rats, rabbits, chickens, quail, turkeys, bovines, sheep, pigs, goats, yaks, etc., which are amenable to genetic manipulation and cloning for rapid expansion of the transgene expressing population. For animals, the desaturase transgene(s) can be adapted for expression in target organelles, tissues and body fluids through modification of the gene regulatory regions. Of particular interest is the production of PUFAs in the breast milk of the host animal. Examples of host microorganisms include Saccharomyces cerevisiae, Saccharomyces carlsbergensis, or other yeast such as Candida, Kluyveromyces or other fungi, for example, filamentous fungi such as Aspergillus, Neurospora, Penicillium, etc. Desirable characteristics of a host microorganism are, for example, that it is genetically well characterized, can be used for high level expression of the product using ultra-high density fermentation, and is on the GRAS (generally recognized as safe) list since the proposed end product is intended for ingestion by humans. Of particular interest is use of a yeast, more particularly baker's yeast (S. cerevisiae), as a cell host in the subject invention. Strains of particular interest are SC334 (Mat α pep4-3 prbl-1122 ura3-52 leu2-3, 112 regl-501 gal1; Gene 83:57-64, 1989, Hovland P. et al.), YTC34 (α ade2-101 his3Δ200 lys2-801 ura3-52; obtained from Dr. T. H. Chang, Ass. Professor of Molecular Genetics, Ohio State University), YTC41 (a/α ura3-52/ura3=52 lys2-801/lys2-801 ade2-101/ade2-101 trp1-Δ1/tpr1-Δ1 his3Δ200/his3Δ200 leu2Δ1/leu2Δ1; obtained from Dr. T. H. Chang, Ass. Professor of Molecular Genetics, Ohio State University), BJ1995 (obtained from the Yeast Genetic Stock Centre, 1021 Donner Laboratory, Berkeley, Calif. 94720), INVSC1 (Mat α hiw3Δ1 leu2 trp1-289 ura3-52; obtained from Invitrogen, 1600 Faraday Ave., Carlsbad, Calif. 92008) and INVSC2 (Mat α his3Δ200 ura3-167; obtained from Invitrogen).

For producing PUFAs in avian species and cells, such as chickens, turkeys, quail and ducks, gene transfer can be performed by introducing a nucleic acid sequence encoding a Δ6 and/or Δ12-desaturase into the cells following procedures known in the art. If a transgenic animal is desired, pluripotent stem cells of embryos can be provided with a vector carrying a desaturase encoding transgene and developed into adult animal (U.S. Pat. No. 5,162,215; Ono et al. (1996) Comparative Biochemistry and Physiology A 113(3):287-292; WO 9612793; WO 9606160). In most cases, the transgene will be modified to express high levels of the desaturase in order to increase production of PUFAs. The transgene can be modified, for example, by providing transcriptional and/or translational regulatory regions that function in avian cells, such as promoters which direct expression in particular tissues and egg parts such as yolk. The gene regulatory regions can be obtained from a variety of sources, including chicken anemia or avian leukosis viruses or avian genes such as a chicken ovalbumin gene.

Production of PUFAs in insect cells can be conducted using baculovirus expression vectors harboring one or more desaturase transgenes. Baculovirus expression vectors are available from several commercial sources such as Clonetech. Methods for producing hybrid and transgenic strains of algae, such as marine algae, which contain and express a desaturase transgene also are provided. For example, transgenic marine algae may be prepared as described in U.S. Pat. No. 5,426,040. As with the other expression systems described above, the timing, extent of expression and activity of the desaturase transgene can be regulated by fitting the polypeptide coding sequence with the appropriate transcriptional and translational regulatory regions selected for a particular use. Of particular interest are promoter regions which can be induced under preselected growth conditions. For example, introduction of temperature sensitive and/or metabolite responsive mutations into the desaturase transgene coding sequences, its regulatory regions, and/or the genome of cells into which the transgene is introduced can be used for this purpose.

The transformed host cell is grown under appropriate conditions adapted for a desired end result. For host cells grown in culture, the conditions are typically optimized to produce the greatest or most economical yield of PUFAs, which relates to the selected desaturase activity. Media conditions which may be optimized include: carbon source, nitrogen source, addition of substrate, final concentration of added substrate, form of substrate added, aerobic or anaerobic growth, growth temperature, inducing agent, induction temperature, growth phase at induction, growth phase at harvest, pH, density, and maintenance of selection. Microorganisms of interest, such as yeast are preferably grown in selected medium. For yeast, complex media such as peptone broth (YPD) or a defined media such as a minimal media (contains amino acids, yeast nitrogen base, and ammonium sulfate, and lacks a component for selection, for example uracil) are preferred. Desirably, substrates to be added are first dissolved in ethanol. Where necessary, expression of the polypeptide of interest may be induced, for example by including or adding galactose to induce expression from a GAL promoter.

Expression in cells of a host animal can likewise be accomplished in a transient or stable manner. Transient expression can be accomplished via known methods, for example infection or lipofection, and can be repeated in order to maintain desired expression levels of the introduced construct (see Ebert, PCT publication WO 94/05782). Stable expression can be accomplished via integration of a construct into the host genome, resulting in a transgenic animal. The construct can be introduced, for example, by microinjection of the construct into the pronuclei of a fertilized egg, or by transfection, retroviral infection or other techniques whereby the construct is introduced into a cell line which may form or be incorporated into an adult animal (U.S. Pat. Nos. 4,873,191; 5,530,177; 5,565,362; 5,366,894; Willmut et al (1997) Nature 385:810). The recombinant eggs or embryos are transferred to a surrogate mother (U.S. Pat. Nos. 4,873,191; 5,530,177; 5,565,362; 5,366,894; Wilmut et al (supra)).

After birth, transgenic animals are identified, for example, by the presence of an introduced marker gene, such as for coat color, or by PCR or Southern blotting from a blood, milk or tissue sample to detect the introduced construct, or by an immunological or enzymological assay to detect the expressed protein or the products produced therefrom (U.S. Pat. Nos. 4,873,191; 5,530,177; 5,565,362; 5,366,894; Wilmut et al (supra)). The resulting transgenic animals may be entirely transgenic or may be mosaics, having the transgenes in only a subset of their cells. The advent of mammalian cloning, accomplished by fusing a nucleated cell with an enucleated egg, followed by transfer into a surrogate mother, presents the possibility of rapid, large-scale production upon obtaining a "founder" animal or cell comprising the introduced construct; prior to this, it was necessary for the transgene to be present in the germ line of the animal for propagation (Wilmut et al (supra)).

Expression in a host animal presents certain efficiencies, particularly where the host is a domesticated animal. For production of PUFAs in a fluid readily obtainable from the host animal, such as milk, the desaturase transgene can be expressed in mammary cells from a female host, and the PUFA content of the host cells altered. The desaturase transgene can be adapted for expression so that it is retained in the mammary cells, or secreted into milk, to form the PUFA reaction products localized to the milk (PCT publication WO 95/24488). Expression can be targeted for expression in mammary tissue using specific regulatory sequences, such as those of bovine α-lactalbumin, α-casein, β-casein, γ-casein, κ-casein, β-lactoglobulin, or whey acidic protein, and may optionally include one or more introns and/or secretory signal sequences (U.S. Pat. No. 5,530,177; Rosen, U.S. Pat. No. 5,565,362; Clark et al., U.S. Pat. No. 5,366,894; Garner et al., PCT publication WO 95/23868). Expression of desaturase transgenes, or antisense desaturase transcripts, adapted in this manner can be used to alter the levels of specific PUFAs, or derivatives thereof, found in the animals milk. Additionally, the desaturase transgene(s) can be expressed either by itself or with other transgenes, in order to produce animal milk containing higher proportions of desired PUFAs or PUFA ratios and concentrations that resemble human breast milk (Prieto et al., PCT publication WO 95/24494).

The desaturated fatty acids may be found in the host microorganism or animal as free fatty acids or in conjugated forms such as acylglycerols, phospholipids, sulfolipids or glycolipids, and may be extracted from the host cell through a variety of means well-known in the art. Such means may include extraction with organic solvents, sonication, supercritical fluid extraction using for example carbon dioxide, and physical means such as presses, or combinations thereof. Of particular interest is extraction with methanol and chloroform. Where desirable, the aqueous layer can be acidified to protonate negatively charged moieties and thereby increase partitioning of desired products into the organic layer. After extraction, the organic solvents can be removed by evaporation under a stream of nitrogen. When isolated in conjugated forms, the products may be enzymatically or chemically cleaved to release the free fatty acid or a less complex conjugate of interest, and can then be subject to further manipulations to produce a desired end product. Desirably, conjugated forms of fatty acids are cleaved with potassium hydroxide.

If further purification is necessary, standard methods can be employed. Such methods may include extraction, treatment with urea, fractional crystallization, HPLC, fractional distillation, silica gel chromatography, high speed centrifugation or distillation, or combinations of these techniques. Protection of reactive groups, such as the acid or alkenyl groups, may be done at any step through known techniques, for example alkylation or iodination. Methods used include methylation of the fatty acids to produce methyl esters. Similarly, protecting groups may be removed at any step. Desirably, purification of fractions containing GLA, SDA, ARA, DHA and EPA may be accomplished by treatment with urea and/or fractional distillation.

The subject invention finds many applications. Probes based on the DNAs of the present invention may find use in methods for isolating related molecules or in methods to detect organisms expressing desaturases. When used as probes, the DNAs or oligonucleotides must be detectable. This is usually accomplished by attaching a label either at an internal site, for example via incorporation of a modified residue, or at the 5' or 3' terminus. Such labels can be directly detectable, can bind to a secondary molecule that is detectably labeled, or can bind to an unlabelled secondary molecule and a detectably labeled tertiary molecule; this process can be extended as long as is practical to achieve a satisfactorily detectable signal without unacceptable levels of background signal. Secondary, tertiary, or bridging systems can include use of antibodies directed against any other molecule, including labels or other antibodies, or can involve any molecules which bind to each other, for example a biotin-streptavidin/avidin system. Detectable labels typically include radioactive isotopes, molecules which chemically or enzymatically produce or alter light, enzymes which produce detectable reaction products, magnetic molecules, fluorescent molecules or molecules whose fluorescence or light-emitting characteristics change upon binding. Examples of labelling methods can be found in U.S. Pat. No. 5,011,770. Alternatively, the binding of target molecules can be directly detected by measuring the change in heat of solution on binding of probe to target via isothermal titration calorimetry, or by coating the probe or target on a surface and detecting the change in scattering of light from the surface produced by binding of target or probe, respectively, as may be done with the BIAcore system.

The PUFAs, or derivatives thereof, made by the disclosed method can be used as dietary substitutes, or supplements, particularly infant formulas, for patients undergoing intravenous feeding or for preventing or treating malnutrition. Typically, human breast milk has a fatty acid profile comprising from about 0.15% to about 0.36% as DHA, from about 0.03% to about 0.13% as EPA, from about 0.30% to about 0.88% as ARA, from about 0.22% to about 0.67% as DGLA, and from about 0.27% to about 1.04% as GLA. Additionally, the predominant triglyceride in human milk has been reported to be 1,3-di-oleoyl-2-palmitoyl, with 2-palmitoyl glycerides reported as better absorbed than 2-oleoyl or 2-lineoyl glycerides (U.S. Pat. No. 4,876,107). Thus, fatty acids such as ARA, DGLA, GLA and/or EPA produced by the invention can be used to alter the composition of infant formulas to better replicate the PUFA composition of human breast milk. In particular, an oil composition for use in a pharmacologic or food supplement, particularly a breast milk substitute or supplement, will preferably comprise one or more of ARA, DGLA and GLA. More preferably the oil will comprise from about 0.3 to 30% ARA, from about 0.2 to 30% DGL, and from about 0.2 to about 30% GLA. In addition to the concentration, the ratios of ARA, DGLA and GLA can be adapted for a particular given end use. When formulated as a breast milk supplement, an oil composition which contains two or more of ARA, DGLA and GLA will be provided in a ratio of about 1:19:30 to about 6:1:0.2, respectively. For example, the breast milk of animals can vary in ratios of ARA, DGLA and DGL ranging from 1:19:30 to 6:1:0.2, which includes intermediate ratios which are preferably about 1:1:1, 1:2:1, 1:1:4. When produced together in a host cell, adjusting the rate and percent of conversion of a precursor substrate such as GLA and DGLA to ARA can be used to precisely control the PUFA ratios. For example, a 5% to 10% conversion rate of DGLA to ARA can be used to produce an ARA to DGLA ratio of about 1:19, whereas a conversion rate of about 75% to 80% can be used to produce an ARA to DGLA ratio of about 6:1. Therefore, whether in a cell culture system or in a host animal, regulating the timing, extent and specificity of desaturase expression as described can be used to modulate the PUFA levels and ratios. And depending on the expression system, e.g., cell culture and animal expressing oil(s) in their milk, the oils also can be isolated and recombined in the desired concentrations and ratios. Amounts of oils providing these ratios of PUFA can be determined following standard protocols. PUFAs, or host cells containing them, also can be used as animal food supplements to alter an animal's tissue or milk fatty acid composition to one more desirable for human or animal consumption.

For dietary supplementation, the purified PUFAs, or derivatives thereof, may be incorporated into cooking oils, fats or margarines formulated so that in normal use the recipient would receive the desired amount. The PUFAs may also be incorporated into infant formulas, nutritional supplements or other food products, and may find use as anti-inflammatory or cholesterol lowering agents.

For pharmaceutical use (human or veterinary), the compositions are generally administered orally but can be administered by any route by which they may be successfully absorbed, e.g., parenterally (i.e. subcutaneously, intramuscularly or intravenously), rectally or vaginally or topically, for example, as a skin ointment or lotion. The PUFAs of the present invention may be administered alone or in combination with a pharmaceutically acceptable carrier or excipient. Where available, gelatin capsules are the preferred form of oral administration. Dietary supplementation as set forth above can also provide an oral route of administration. The unsaturated acids of the present invention may be administered in conjugated forms, or as salts, esters, amides or prodrugs of the fatty acids. Any pharmaceutically acceptable salt is encompassed by the present invention; especially preferred are the sodium, potassium or lithium salts. Also encompassed are the N-alkylpolyhydroxamine salts, such as N-methyl glucamine, found in PCT publication WO 96/33155. The preferred esters are the ethyl esters. As solid salts, the PUFAs also can be administered in tablet form. For intravenous administration, the PUFAs or derivatives thereof may be incorporated into commercial formulations such as Intralipids. The typical normal adult plasma fatty acid profile comprises 6.64 to 9.46% of ARA, 1.45 to 3.11% of DGLA, and 0.02 to 0.08% of GLA. These PUFAs or their metabolic precursors can be administered, either alone or in mixtures with other PUFAs, to achieve a normal fatty acid profile in a patient. Where desired, the individual components of formulations may be individually provided in kit form, for single or multiple use. A typical dosage of a particular fatty acid is from 0.1 mg to 20 g, or even 100 g daily, and is preferably from 10 mg to 1, 2, 5 or 10 g daily as required, or molar equivalent amounts of derivative forms thereof. Parenteral nutrition compositions comprising from about 2 to about 30 weight percent fatty acids calculated as triglycerides are encompassed by the present invention; preferred is a composition having from about 1 to about 25 weight percent of the total PUFA composition as GLA (U.S. Pat. No. 5,196,198). Other vitamins, and particularly fat-soluble vitamins such as vitamin A, D, E and L-carnitine can optionally be included. Where desired, a preservative such as α tocopherol may be added, typically at about 0.1% by weight.

The following examples are presented by way of illustration, not of limitation.

EXAMPLES Example 1 Construction of a cDNA Library from Mortierella alpina Example 2 Isolation of a Δ6-desaturase Nucleotide Sequence from Mortierella alpina Example 3 Identification of Δ6-desaturases Homologous to the Mortierella alpina Δ6-desaturase Example 4 Isolation of a Δ12-desaturase Nucleotide Sequence from Mortierella alpina Example 5 Expression of M. alpina Desaturase Clones in Baker's Yeast Example 6 Initial Optimization of Culture Conditions Example 7 Distribution of PUFAs in Yeast Lipid Fractions Example 8 Further Culture Optimization and Coexpression of Δ6 and Δ12-desaturases Example 1 Construction of a cDNA Library from Mortierella alpina

Total RNA was isolated from a 3 day old PUFA-producing culture of Mortierella alpina using the protocol of Hoge et al. (1982) Experimental Mycology 6:225-232. The RNA was used to prepare double-stranded cDNA using BRL's lambda-ZipLox system following the manufacture's instructions. Several size fractions of the M. alpina cDNA were packaged separately to yield libraries with different average-sized inserts. A "full-length" library contains approximately 3×10⁶ clones with an average insert size of 1.77 kb. The "sequencing-grade" library contains approximately 6×10⁵ clones with an average insert size of 1.1 kb.

Example 2 Isolation of a Δ6-desaturase Nucleotide Sequence from Mortierella alpina

A nucleic acid sequence from a partial cDNA clone, Ma524, encoding a Δ6 fatty acid desaturase from Mortierella alpina was obtained by random sequencing of clones from the M. alpina cDNA sequencing grade library described in Example 1. cDNA-containing plasmids were excised as follows:

Five μl of phage were combined with 100 μl of E. coli DH10B(ZIP) grown in ECLB plus 10 μg/ml kanamycin, 0.2% maltose, and 10 mM MgSO₄ and incubated at 37 degrees for 15 minutes. 0.9 ml SOC was added and 100 μl of the bacteria immediately plated on each of 10 ECLB+50 μg Pen plates. No 45 minute recovery time was needed. The plates were incubated overnight at 37°. Colonies were picked into ECLB+50 μg Pen media for overnight cultures to be used for making glycerol stocks and miniprep DNA. An aliquot of the culture used for the miniprep is stored as a glycerol stock. Plating on ECLB+50 μg Pen/ml resulted in more colonies and a greater proportion of colonies containing inserts than plating on 100 μg/ml Pen.

Random colonies were picked and plasmid DNA purified using Qiagen miniprep kits. DNA sequence was obtained from the 5' end of the cDNA insert and compared to the National Center for Biotechnology Information (NCBI) nonredundant database using the BLASTX algorithm. Ma524 was identified as a putative desaturase based on DNA sequence homology to previously identified desaturases.

A full-length cDNA clone was isolated from the M. alpina full-length library and designated pCGN5532. The cDNA is contained as a 1617 bp insert in the vector pZL1 (BRL) and, beginning with the first ATG, contains an open reading frame encoding 457 amino acids. The three conserved "histidine boxes" known to be conserved among membrane-bound deaturases (Okuley, et al. (1994) The Plant Cell 6:147-158) were found to be present at amino acid positions 172-176, 209-213, and 395-399 (see FIG. 3). As with other membrane-bound Δ6-desaturases the final HXXHH histidine box motif was found to be QXXHH. The amino acid sequence of Ma524 was found to display significant homology to a portion of a Caenorhabditis elegans cosmid, WO6D2.4, a cytochrome b5/desaturase fusion protein from sunflower, and the Synechocystis and Spirulina Δ6-desaturases. In addition, Ma524 was shown to have homology to the borage Δ6-desaturase amino sequence (PCT publication W) 96/21022). Ma524 thus appears to encode a Δ6-desaturase that is related to the borage and algal Δ6-desaturases.

Surprisingly, the amino terminus of the encoded protein was found to exhibit significant homology to cytochrome b5 proteins. The Mortierella cDNA clone appears to represent a fusion between a cytochrome b5 and a fatty acid desaturase. Since cytochrome b5 is believed to function as the electron donor for membrane-bound desaturase enzymes, it is possible that the N-terminal cytochrome b5 domain of this desaturase protein is involved in its function. This may be advantageous when expressing the desaturase in heterologous systems for PUFA production. However, it should be noted that, although the amino acid sequences of Ma524 and the borage Δ6 were found to contain regions of homology, the base compositions of the cDNAs were shown to be significantly different. For example, the borage cDNA was shown to have an overall base composition of 60% A/T, with some regions exceeding 70%, while Ma524 was shown to have an average of 44% A/T base composition, with no regions exceeding 60%. This may have implications for expressing the cDNAs in microorganisms or animals which favor different base compositions. It is known that poor expression of recombinant genes can occur when the host prefers a base composition different from that of the introduced gene. Mechanisms for such poor expression include decreased stability, cryptic splice sites, and/or translatability of the mRNA and the like.

Example 3 Identification of Δ6-desaturases Homologous to the Mortierella Alpina Δ6-desaturase

Nucleic acid sequences that encode putative Δ6-desaturases were identified through a BLASTX search of the Expressed Sequence Tag ("EST") databases through NCBI using the Ma524 amino acid sequence. Several sequences showed significant homology. In particular, the deduced amino acid sequence of two Arabidopsis thaliana sequences, (accession numbers F13728 and T42806) showed homology to two different regions of the deduced amino acid sequence of Ma524. The following PCR primers were designed: ATTS4723-FOR (complementary to F13728) 5' CUACUACUACUAGGAGTCCTCTACGGTGTTTTG (SEQ ID NO:13) and T42806-REV (complementary to T42806) 5' CAUCAUCAUCAUATGATGCTCAAGCTGAAACTG (SEQ ID NO:14). Five μg of total RNA isolated from developing siliques of Arabidopsis thaliana was reverse transcribed using BRL Superscript RTase and the primer TSyn (5'-CCAAGCTTCTGCAGGAGCTCTTTTTTTTTTTTTTT-3') (SEQ ID NO:12). PCR was carried out in a 50 ul volume containing: template derived from 25 ng total RNA, 2 pM each primer, 200 μM each deoxyribonucleotide triphosphate, 60 mM Tris-Cl, pH 8.5, 15 mM (NH₄)₂ SO₄, 2 mM MgCl₂, 0.2 U Taq Polymerase. Thermocylces conditions were as follows: 94 degrees for 30 sec., 50 degrees for 30 sec., 72 degrees for 30 sec. PCR was continued for 35 cycles followed by an additional extension at 72 degrees for 7 minutes. PCR resulted in a fragment of approximately ˜750 base pairs which was subcloned, named 12-5, and sequenced. Each end of this fragment was formed to correspond to the Arabidopsis ESTs from which the PCR primers were designed. The putative amino acid sequence of 12-5 was compared to that of Ma524, and ESTs from human (W28140), mouse (W53753), and C. elegans (R05219) (see FIG. 4). Homology patterns with the Mortierella Δ6- desaturase indicate that these sequences represent putative desaturase polypeptides. Based on this experiment approach, it is likely that the full-length genes can be cloned using probes based on the EST sequences. Following the cloning, the genes can then be placed into expression vectors, expressed in host cells, and their specific Δ6- or other desaturase activity can be determined as described below.

Example 4 Isolation of a Δ12-desaturase Nucleotide Sequence from Mortierella alpina

Based on the fatty acids it accumulates, it seemed probable that Mortierella alpina has an ω6 type desaturase. The ω6-desaturase is responsible for the production of linoleic acid (18:2) from oleic acid (18:1). Linoleic acid (18:2) is a substrate for a Δ6-desaturase. This experiment was designed to determine if Mortierella alpina has a Δ12-desaturase polypeptide, and if so, to identify the corresponding nucleotide sequence.

A random colony from the M. alpina sequencing grade library, Ma648, was sequenced and identified as a putative desaturase based on DNA sequence homology to previously identified desaturases, as described for Ma524 (see Example 2). The deduced amino acid sequence from the 5' end of the Ma648 cDNA displays significant homology to soybean microsomal ω6 (Δ12) desaturase (accession #L43921) as well as castor bean oleate 12-hydroxylase (accession #U22378). In addition, homology was observed when compared to a variety of other ω6 (Δ12) and ω3 (Δ15) fatty acid desaturase sequences.

Example 5 Expression of M. alpina Desaturase Clones in Baker's Yeast

Yeast Transformation

Lithium acetate transformation of yeast was performed according to standard protocols (Methods in Enzymology, Vol. 194, p. 186-187, 1991). Briefly, yeast were grown in YPD at 30° C. Cells were spun down, resuspended in TE, spun down again, resuspended in TE containing 100 mM lithium acetate, spun down again, and resuspended in TE/lithium acetate. The resuspended yeast were incubated at 30° C. for 60 minutes with shaking. Carrier DNA was added, and the yeast were aliquoted into tubes. Transforming DNA was added, and the tubes were incubated for 30 min. at 30° C. PEG solution (35% (w/v) PEG 4000, 100 mM lithium acetate, TE pH7.5) was added followed by a 50 min. incubation at 30° C. A 5 min. heat shock at 42° C. was performed, the cells were pelleted, washed with TE, pelleted again and resuspended in TE. The resuspended cells were then plated on selective media.

Desaturase Expression in Transformed Yeast

cDNA clones from Mortierella alpina were screened for desaturase activity in baker's yeast. A canola Δ15-desaturase (obtained by PCR using 1^(st) strand cDNA from Brassica napus cultivar 212/86 seeds using primers based on the published sequence (Arondel et al. Science 258:1353-1355)) was used as a positive control. The Δ15-desaturase gene and the gene from cDNA clones Ma524 and Ma648 were put in the expression vector pYES2 (Invitrogen), resulting in plasmids pCGR-2, pCGR-5 and pCGR-7, respectively. These plasmids were transfected into S. cerevisiae yeast strain 334 and expressed after induction with galactose and in the presence of substrates that allowed detection of specific desaturase activity. The control strain was S. cerevisiae strain 334 containing the unaltered pYES2 vector. The substrates used, the products produced and the indicated desaturase activity were: DGLA (conversion to ARA would indicate Δ5-desaturase activity), linoleic acid (conversion to GLA would indicate Δ6-desaturase activity; conversion to ALA would indicate Δ15-desaturase activity), oleic acid (an endogenous substrate made by S. cerevisiae, conversion to linoleic acid would indicate Δ12-desaturase activity, which S. cerevisiae lacks), or ARA (conversion to EPA would indicate Δ17-desaturase activity).

Cultures were grown for 48-52 hours at 15° C. in the presence of a particular substrate. Lipid fractions were extracted for analysis as follows: Cells were pelleted by centrifugation, washed once with sterile ddH₂ 0, and repelleted. Pellets were vortexed with methanol; chloroform was added along with tritridecanoin (as an internal standard). The mixtures were incubated for at least one hour at room temperature or at 4° C. overnight. The chloroform layer was extracted and filtered through a Whatman filter with one gram of anhydrous sodium sulfate to remove particulates and residual water. The organic solvents were evaporated at 40° C. under a stream of nitrogen. The extracted lipids were then derivatized to fatty acid methyl esters (FAME) for gas chromatography analysis (GC) by adding 2 ml of 0.5 N potassium hydroxide in methanol to a closed tube. The samples were heated to 95° C. to 100° C. for 30 minutes and cooled to room temperature. Approximately 2 ml of 14% boron trifluoride in methanol was added and the heating repeated. After the extracted lipid mixture cooled, 2 ml of water and 1 ml of hexane were added to extract the FAME for analysis by GC. The percent conversion was calculated by dividing the product produced by the sum of (the product produced and the substrate added) and then multiplying by 100. To calculate the oleic acid percent conversion, as no substrate was added, the total linoleic acid produced was divided by the sum of oleic acid and linoleic acid produced, then multiplying by 100. The desaturase activity results are provided in Table 1 below.

                  TABLE 1                                                          ______________________________________                                         M. Alpina Desaturase Expression in Baker's Yeast                                                             % CONVERSION                                       CLONE ENZYME ACTIVITY OF SUBSTRATE                                           ______________________________________                                         pCGR-2     Δ6       0      (18:2 to 18:3w6)                                (canola Δ15 Δ15 16.3 (18:2 to 18:3w3)                              desaturase) Δ5 2.0 (20:3 to 20:4w6)                                       Δ17 2.8 (20:4 to 20:5w3)                                                 Δ12 1.8 (18:1 to 18:2w6)                                                pCGR-5 Δ6 6.0                                                            (M. alpina Δ15 0                                                         Ma524 Δ5 2.1                                                              Δ17 0                                                                    Δ12 3.3                                                                 pCGR-7 Δ6 0                                                              (M. alpina Δ15 3.8                                                       Ma648) Δ5 2.2                                                             Δ17 0                                                                    Δ12 63.4                                                              ______________________________________                                    

The Δ15-desaturase control clone exhibited 16.3% conversion of the substrate. The pCGR-5 clone expressing the Ma524 cDNA showed 6% conversion of the substrate to GLA, indicating that the gene encodes a Δ6-desaturase. The pCGR-7 clone expressing the Ma648 cDNA converted 63.4% conversion of the substrate to LA, indicating that the gene encodes a Δ12-desaturase. The background (non-specific conversion of substrate) was between 0-3% in these cases. We also found substrate inhibition of the activity by using different concentrations of the substrate. When substrate was added to 100 μM, the percent conversion to product dropped compared to when substrate was added to 25 μM (see below). Additionally, by varying the substrate concentration between 5 μM and 200 μM, conversion ratios were found to range between about 5% to about 75% greater. These data show that desaturases with different substrate specificities can be expressed in a heterologous system and used to produce poly-unsaturated long chain fatty acids.

Table 2 represents fatty acids of interest as a percent of the total lipid extracted from the yeast host S. cerevisiae 334 with the indicated plasmid. No glucose was present in the growth media. Affinity gas chromatography was used to separate the respective lipids. GC/MS was employed to verify the identity of the product(s). The expected product for the B. napus Δ15-desaturase, α-linolenic acid, was detected when its substrate, linoleic acid, was added exogenously to the induced yeast culture. This finding demonstrates that yeast expression of a desaturase gene can produce functional enzyme and detectable amounts of product under the current growth conditions. Both exogenously added substrates were taken up by yeast, although slightly less of the longer chain PUFA, dihomo-γ-linolenic acid (20:3), was incorporated into yeast than linoleic acid (18:2) when either was added in free form to the induced yeast cultures. γ-linolenic acid was detected when linoleic acid was present during induction and expression of S. cerevisiae 334 (pCGR-5). The presence of this PUFA demonstrates Δ6-desaturase activity from pCGR-5 (MA524). Linoleic acid, identified in the extracted lipids from expression of S. cerevisiae 334 (pCGR-7), classifies the cDNA MA648 from M. alpina as the Δ12-desaturase.

                                      TABLE 2                                      __________________________________________________________________________     Fatty Acid as a Percentage of Total Lipid Extracted from Yeast                 Plasmid                                                                          In Yeast 18:2 α-18:3 γ-18:3 20:3 20:4 18:1* 18:2                   (enzyme) Incorporated Produced Produced Incorporated Produced Present                                            Produced                                   __________________________________________________________________________     pYES2                                                                               66.9  0    0    58.4  0    4   0                                            (control)                                                                      pCGR-2 60.1   5.7 0 50.4 0 0.7 0                                               (Δ15)                                                                    pCGR-5 62.4 0   4.0 49.9 0 2.4 0                                               (Δ6)                                                                     pCGR-7 65.6 0 0 45.7 0 7.1  12.2                                               (Δ12)                                                                  __________________________________________________________________________      100 μM substrate added                                                      *18:1 is an endogenous fatty acid in yeast                                     Key To Tables                                                                  18:1 = oleic acid                                                              18:2 = linoleic acid                                                           18:3 = linolenic acid                                                          18:3 = linolenic acid                                                          18:4 = stearidonic acid                                                        20:3 = dihomolinolenic acid                                                    20:4 = arachidonic acid                                                  

Example 6 Optimization of Culture Conditions

Table 3A shows the effect of exogenous free fatty acid substrate concentration on yeast uptake and conversion to fatty acid product as a percentage of the total yeast lipid extracted. In all instances, low amounts of exogenous substrate (1-10 μM) resulted in low fatty acid substrate uptake and product formation. Between 25 and 50 μM concentration of free fatty acid in the growth and induction media gave the highest percentage of fatty acid product formed, while the 100 μM concentration and subsequent high uptake into yeast appeared to decrease or inhibit the desaturase activity. The amount of fatty acid substrate for yeast expressing Δ12-desaturase was similar under the same growth conditions, since the substrate, oleic acid, is an endogenous yeast fatty acid. The use of α-linolenic acid as an additional substrate for pCGR-5 (Δ6) produced the expected product, stearidonic acid (Table 3A). The feedback inhibition of high fatty acid substrate concentration was well illustrated when the percent conversion rates of the respective fatty acid substrates to their respective products were compared in Table 3B. In all cases, 100 μM substrate concentration in the growth media decreased the percent conversion to product. The uptake of α-linolenic was comparable to other PUFAs added in free form, while the Δ6-desaturase percent conversion, 3.8-17.5%, to the product stearidonic acid was the lowest of all the substrates examined (Table 3B). The effect of media, such as YPD (rich media) versus minimal media with glucose on the conversion rate of Δ12-desaturase was dramatic. Not only did the conversion rate for oleic to linoleic acid drop, (Table 3B) but the percent of linoleic acid formed also decreased by 11% when rich media was used for growth and induction of yeast desaturase Δ12 expression (Table 3A). The effect of media composition was also evident when glucose was present in the growth media for Δ6-desaturase, since the percent of substrate uptake was decreased at 25 μM (Table 3A). However, the conversion rate remained the same and percent product formed decreased for Δ6-desaturase for in the presence of glucose.

                  TABLE 3A                                                         ______________________________________                                         Effect of Added Substrate on the Percentage of Incorporated                      Substrate and Product Formed in Yeast Extracts                                 Plasmid     pCGR-2    PcGR-5  pCGR-5  pCGR-7                                   in Yeast (Δ15) (Δ6) (Δ6) (Δ12)                       ______________________________________                                         substrate/product                                                                        18:2/α-18:3                                                                        18:2/γ-18:3                                                                        α-18:3/18:4                                                                      18:1*/18:2                                  1 μM sub. ND 0.9/0.7 ND ND                                                  10 μM sub. ND 4.2/2.4 10.4/2.2 ND                                           25 μM sub. ND 11/3.7 18.2/2.7 ND                                            25 μM⋄ sub. 36.6/7.2⋄ 25.1/10.3⋄ ND                                                    6.6/15.8⋄                           50 μM sub. 53.1/6.5⋄ ND 36.2/3 10.8/13.sup.+                       100 μM sub. 60.1/5.7⋄ 62.4/4⋄ 47.7/1.9 10/24.8            ______________________________________                                    

                  TABLE 3B                                                         ______________________________________                                         Effect of Substrate Concentration in Media on the Percent Conversion            of Fatty Acid Substrate to Product in Yeast Extracts                            Plasmid    pCGR-2  pCGR-5  pCGR-5   pCGR-7                                                                          in Yeast (Δ15) (Δ6)                                               (Δ6) (Δ12)                   ______________________________________                                         substrate→                                                                       18:2→                                                                           18:2→γ18:3                                                                  α-18:3→18:4                                                                18:1*→18:2                            product α-18:3                                                            1 μM sub. ND 43.8 ND ND                                                     10 μM sub. ND 36.4 17.5 ND                                                  25 μM sub. ND 25.2 12.9 ND                                                  25 μM⋄ sub. 16.4⋄ 29.1⋄ ND 70.5⋄                                               50 μM sub. 10.9⋄ ND 7.7                                           54.6.sup.+                                   100 μM sub. 8.7⋄ 6⋄ 3.8 71.3                              ______________________________________                                          ⋄no glucose in media                                                   .sup.+ Yeast peptone broth (YPD)                                               *18:1 is an endogenous yeast lipid                                             sub. is substrate concentration                                                ND (not done)                                                            

Table 4 shows the amount of fatty acid produced by a recombinant desaturase from induced yeast cultures when different amounts of free fatty acid substrate were used. Fatty acid weight was determined since the total amount of lipid varied dramatically when the growth conditions were changed, such as the presence of glucose in the yeast growth and induction media. To better determine the conditions when the recombinant desaturase would produce the most PUFA product, the quantity of individual fatty acids were examined. The absence of glucose dramatically reduced by three fold the amount of linoleic acid produced by recombinant Δ12-desaturase. For the Δ12-desaturase the amount of total yeast lipid was decreased by almost half in the absence of glucose. Conversely, the presence of glucose in the yeast growth media for Δ6-desaturase drops the γ-linolenic acid produced by almost half, while the total amount of yeast lipid produced was not changed by the presence/absence of glucose. This points to a possible role for glucose as a modulator of Δ6-desaturase activity.

                  TABLE 4                                                          ______________________________________                                         Fatty Acid Produced in μg from Yeast Extracts                                    Plasmid in Yeast                                                                           pCGR-5      pCGR-5                                                                               pCGR-7                                        (enzyme) (Δ6) (Δ6) (Δ12)                                   ______________________________________                                         product      Υ-18:3                                                                             18:4    18:2*                                            1 μM sub. 1.9 ND ND                                                        10 μM sub. 5.3 4.4 ND                                                       25 μM sub. 10.3 8.7 115.7                                                   25 μM ⋄ sub. 29.6 ND 39 ⋄                                 ______________________________________                                          ⋄ no glucose in media                                                  sub. is substrate concentration                                                ND (not done)                                                                  *18:1, the substrate, is an endogenous yeast lipid                       

Example 7 Distribution of PUFAs in Yeast Lipid Fractions

Table 5 illustrates the uptake of free fatty acids and their new products formed in yeast lipids as distributed in the major lipid fractions. A total lipid extract was prepared as described above. The lipid extract was separated on TLC plates, and the fractions were identified by comparison to standards. The bands were collected by scraping, and internal standards were added. The fractions were then saponified and methylated as above, and subjected to gas chromatography. The gas chromatograph calculated the amount of fatty acid by comparison to a standard. The phospholipid fraction contained the highest amount of substrate and product PUFAs for Δ6-desaturase activity. It would appear that the substrates are accessible in the phospholipid form to the desaturases.

                  TABLE 5                                                          ______________________________________                                         Fatty Acid Distribution in Various Yeast Lipid Fractions in μg                                          Free                                                                                         Fatty acid Phos- Di- Fatty                                                    Cholesterol                             fraction pholipid glyceride Acid Triglyceride Ester                          ______________________________________                                         SC (pCGR-5)                                                                             166.6   6.2      15   18.2    15.6                                      substrate 18:2                                                                 SC (pCGR-5) 61.7 1.6 4.2 5.9 1.2                                               product γ-18:3                                                         ______________________________________                                          SC = S. cerevisiae (plasmid)                                             

Example 8 Further Culture Optimization and Coexpression of Δ6 and Δ12-desaturases

This experiment was designed to evaluate the growth and induction conditions for optimal activities of desaturases in Saccharomyces cerevisiae. A Saccharomyces cerevisiae strain (SC334) capable of producing γ-linolenic acid (GLA) was developed, to assess the feasibility of production of PUFA in yeast. The genes for Δ6 and Δ12-desaturases from M. alpina were coexpressed in SC334. Expression of Δ12-desaturase converted oleic acid (present in yeast) to linoleic acid. The linoleic acid was used as a substrate by the Δ6-desaturase to produce GLA. The quantity of GLA produced ranged between 5-8% of the total fatty acids produced in SC334 cultures and the conversion rate of linoleic acid to γ-linolenic acid ranged between 30% to 50%. The induction temperature was optimized, and the effect of changing host strain and upstream promoter sequences on expression of Δ6 and Δ12 (MA 524 and MA 648 respectively) desaturase genes was also determined.

Plasmid Construction

The cloning of pCGR5 as well as pCGR7 has been discussed above. To construct pCGR9a and pCGR9b, the Δ6 and Δ12-desaturase genes were amplified using the following sets of primers. The primers pRDS1 and 3 had Xhol site and primers pRDS2 and 4 had Xbal site (indicated in bold).

I. Δ6-Desaturase Amplification Primers

a. pRDS1 tac caa ctc gag aaa atg gct gct gct ccc agt gtg agg (SEQ ID NO:15)

b. pRDS2 aac tga tct aga tta ctg cgc ctt acc cat ctt gga ggc (SEQ ID NO:16)

II. Δ12-Desaturase Amplification Primers

a. pRDS3 tac caa ctc gag aaa atg gca cct ccc aac act atc gat (SEQ ID NO:17)

b. pRDS4 aac tga tct aga tta ctt ctt gaa aaa gac cac gtc tcc (SEQ ID NO:18)

The pCGR5 and pCGR7 constructs were used as template DNA for amplification of Δ6 and Δ12-desaturase genes, respectively. The amplified products were digested with Xbal and Xho to create "sticky ends". The PCR amplified Δ6-desaturase with Xhol-Xbal ends as cloned into pCGR7, which was also cut with Xho-l-Xbal. This procedure placed the Δ6-desaturase behind the Δ12-desaturase, under the control of an inducible promoter GAL1. This construct was designated pCGR9a. Similarly, to construct pCGR9b, the Δ12-desaturase with XhoI-XbaI ends was cloned in the XhoI-XbaI sites of pCGR5. In pCGR9b the Δ12-desaturase was behind the Δ6-desaturase gene, away from the GAL promoter.

To construct pCGR10, the vector pRS425, which contains the constitutive Glyceraldehyde 3-Phosphate Dehydrogenase (GPD) promoter, was digested with BamHl and pCGR5 was digested with BamHl-Xhol to release the Δ6-desaturase gene. This Δ6-desaturase fragment and BamHl cut pRS425 were filled using Klenow Polymerase to create blunt ends and ligated, resulting in pCGR10a and pCGR10b containing the Δ6-desaturase gene in the sense and antisense orientation, respectively. To construct pCGR11 and pCGR12, the Δ6 and Δ12-desaturase genes were isolated from pCGR5 and pCGR7, respectively, using an EcoRl-XhoI double digest. The EcoRl-Xhol fragments of Δ6 and Δ12-desaturases were cloned into the pYX242 vector digested with EcoRl-Xhol. The pYX242 vector has the promoter of TPl (a yeast housekeeping gene), which allows constitutive expression.

Yeast Transformation and Expression

Different combinations of pCGR5, pCGR7, pCGR9a, pCGR9b, pCGR10a, pCGR11 and pCGR12 were introduced into various host strains of Saccharomyces cerevisiae. Transformation was done using PEG/LiAc protocol (Methods in Enzymology Vol. 194 (1991): 186-187). Transformants were selected by plating on synthetic media lacking the appropriate amino acid. The pCGR5, pCGR7, pCGR9a and pCGR9b can be selected on media lacking uracil. The pCGR10, pCGR11 and pCGR12 constructs can be selected on media lacking leucine. Growth of cultures and fatty acid analysis was performed as in Example 5 above.

Production of GLA

Production of GLA requires the expression of two enzymes (the Δ6 and Δ12-desaturases), which are absent in yeast. To express these enzymes at optimum levels the following constructs or combinations of constructs, were introduced into various host strains:

1) pCGR9a/SC334

2) pCGR9b/SC334

3) pCGR10a and pCGR7/SC334

4) pCGR11 and pCGR7/SC334

5) pCGR12 and pCGR5/SC334

6) pCGR10a and pCGR7/DBY746

7) pCGR10a and pCGR7/DBY746

The pCGR9a construct has both the Δ6 and Δ12-desaturase genes under the control of an inducible GAL promoter. The SC334 host cells transformed with this construct did not show any GLA accumulation in total fatty acids (FIGS. 6A and B, lane 1). However, when the Δ6 and Δ12-desaturase genes were individually controlled by the GAL promoter, the control constructs were able to express Δ6 and Δ12-desaturase, as evidenced by the conversion of their respective substrates to products. The Δ12-desaturase gene in pCGR9a was expressed as evidenced by the conversion of 18:1n-9 to 18:2n-6 in pCGR9a/SC334, while the Δ6-desaturase gene was not expressed/active, because the 18:2n-6 was not being converted to 18:3n-6 (FIGS. 6A and B, lane 1).

The pCGR9b construct also had both the Δ6 and Δ12-desaturase genes under the control of the GAL promoter but in an inverse order compared to pCGR9a. In this case, very little GLA (<1%) was seen in pCGR9b/SC334 cultures. The expression of Δ12 was also very low, as evidenced by the low percentage of 18:2 in the total fatty acids (FIGS. 6A and B, lane 1).

To test if expressing both enzymes under the control of independent promoters would increase GLA production, the Δ6-desaturase gene was cloned into the pRS425 vector. The construct of pCGR10a has the Δ6-desaturase in the correct orientation, under control of constitutive GPD promoter. The pCGR10b has the Δ6-desaturase gene in the inverse orientation, and serves as the negative control. The pCGR10a/SC334 cells produced significantly higher levels of GLA (5% of the total fatty acids, FIG. 6, lane 3), compared to pCGR9a. Both the Δ6 and Δ12-desaturase genes were expressed at high level because the conversion of 18:1→18:2 was 65%, while the conversion of 18:2→18:3 (Δ6-desaturase) was 30% (FIG. 6, lane 3). As expected, the negative control pCGR10b/SC334 did not show any GLA.

To further optimize GLA production, the Δ6 and Δ12 genes were introduced into the PYX242 vector, creating pCGR11 and pCGR12 respectively. The PYX242 vector allows for constitutive expression by the TP1 promoter (Alber, T. and Kawasaki, G. (1982). J. Mol. & Appl. Genetics 1: 419). The introduction of pCGR11 and pCGR7/SC334 gene resulted in approximately 8% of GLA in total fatty acids of SC334. The rate of conversion of 18:1→18:2 and 18:2→18:3 was approximately 50% and 44% respectively (FIG. 6A and B, lane 4). The presence of pCGR12 and pCGR5 in SC334 resulted in 6.6% GLA in total fatty acids with a conversion rate of approximately 50% for both 18:1 to 18:2 and 18:2 to 18:3, respectively (FIG. 6A and B, lane 5). Thus although the quantity of GLA in total fatty acids was higher in the pCGR11/pCGR7 combination of constructs, the conversion rates of substrate to product were better for the pCGR12/pCGR5 combination.

To determine if changing host strain would increase GLA production, pCGR10a and pCGR7 were introduced into the host strain BJ1995 and DBY746 (obtained from the Yeast Genetic Stock Centre, 1021 Donner Laboratory, Berkeley, Calif. 94720. The genotype of strain DBY746 is Matα, his3-Δ1, leu2-3, leu2-112, ura3-32, trp1-289, gal). The results are shown in FIG. 7. Changing host strain to BJ1995 did not improve the GLA production, because the quantity of GLA was only 1.31% of total fatty acids and the conversion rate of 18:1→18:2 was approximately 17% in BJ1995. No GLA was observed in DBY746 and the conversion of 18:1→18:2 was very low (<1% in control) suggesting that a cofactor required for the expression of Δ12-desaturase might be missing in DB746 (FIG. 7, lane 2).

To determine the effect of temperature on GLA production, pCGR10a and pCGR7/SC334 cultures were grown at 15° C. and 30° C. Higher levels of GLA were found in cultures grown and induced at 15° C. than those in cultures grown at 30° C. (4.23% vs. 1.68%). This was due to a lower conversion rate of 18:2→18:3 at 30° C. (11.6% vs. 29% in 15° C.) cultures, despite a higher conversion of 18:1→18:2 (65% vs. 60% at 30° C. (FIG. 8). These results suggest that Δ12 and Δ6 may have different optimal expression temperatures.

Of the various parameters examined in this study, temperature of growth, yeast host strain and media components had the most significant impact on the expression of desaturase, while timing of substrate addition and concentration of inducer did not significantly affect desaturase expression.

These data show that two DNAs encoding desaturases that can convert LA to GLA or oleic acid to LA can be isolated from Mortierella alpina and can be expressed, either individually or in combination, in a heterologous system and used to produce poly-unsaturated long chain fatty acids. Exemplified is the production of GLA from oleic acid by expression of Δ12- and Δ6-desaturases in yeast.

All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

    __________________________________________________________________________     #             SEQUENCE LISTING                                                    - -  - - (1) GENERAL INFORMATION:                                              - -    (iii) NUMBER OF SEQUENCES: 18                                           - -  - - (2) INFORMATION FOR SEQ ID NO:1:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1617 base - #pairs                                                 (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                - - CGACACTCCT TCCTTCTTCT CACCCGTCCT AGTCCCCTTC AACCCCCCTC TT -             #TGACAAAG     60                                                                  - - ACAACAAACC ATGGCTGCTG CTCCCAGTGT GAGGACGTTT ACTCGGGCCG AG -             #GTTTTGAA    120                                                                  - - TGCCGAGGCT CTGAATGAGG GCAAGAAGGA TGCCGAGGCA CCCTTCTTGA TG -             #ATCATCGA    180                                                                  - - CAACAAGGTG TACGATGTCC GCGAGTTCGT CCCTGATCAT CCCGGTGGAA GT -             #GTGATTCT    240                                                                  - - CACGCACGTT GGCAAGGACG GCACTGACGT CTTTGACACT TTTCACCCCG AG -             #GCTGCTTG    300                                                                  - - GGAGACTCTT GCCAACTTTT ACGTTGGTGA TATTGACGAG AGCGACCGCG AT -             #ATCAAGAA    360                                                                  - - TGATGACTTT GCGGCCGAGG TCCGCAAGCT GCGTACCTTG TTCCAGTCTC TT -             #GGTTACTA    420                                                                  - - CGATTCTTCC AAGGCATACT ACGCCTTCAA GGTCTCGTTC AACCTCTGCA TC -             #TGGGGTTT    480                                                                  - - GTCGACGGTC ATTGTGGCCA AGTGGGGCCA GACCTCGACC CTCGCCAACG TG -             #CTCTCGGC    540                                                                  - - TGCGCTTTTG GGTCTGTTCT GGCAGCAGTG CGGATGGTTG GCTCACGACT TT -             #TTGCATCA    600                                                                  - - CCAGGTCTTC CAGGACCGTT TCTGGGGTGA TCTTTTCGGC GCCTTCTTGG GA -             #GGTGTCTG    660                                                                  - - CCAGGGCTTC TCGTCCTCGT GGTGGAAGGA CAAGCACAAC ACTCACCACG CC -             #GCCCCCAA    720                                                                  - - CGTCCACGGC GAGGATCCCG ACATTGACAC CCACCCTCTG TTGACCTGGA GT -             #GAGCATGC    780                                                                  - - GTTGGAGATG TTCTCGGATG TCCCAGATGA GGAGCTGACC CGCATGTGGT CG -             #CGTTTCAT    840                                                                  - - GGTCCTGAAC CAGACCTGGT TTTACTTCCC CATTCTCTCG TTTGCCCGTC TC -             #TCCTGGTG    900                                                                  - - CCTCCAGTCC ATTCTCTTTG TGCTGCCTAA CGGTCAGGCC CACAAGCCCT CG -             #GGCGCGCG    960                                                                  - - TGTGCCCATC TCGTTGGTCG AGCAGCTGTC GCTTGCGATG CACTGGACCT GG -             #TACCTCGC   1020                                                                  - - CACCATGTTC CTGTTCATCA AGGATCCCGT CAACATGCTG GTGTACTTTT TG -             #GTGTCGCA   1080                                                                  - - GGCGGTGTGC GGAAACTTGT TGGCGATCGT GTTCTCGCTC AACCACAACG GT -             #ATGCCTGT   1140                                                                  - - GATCTCGAAG GAGGAGGCGG TCGATATGGA TTTCTTCACG AAGCAGATCA TC -             #ACGGGTCG   1200                                                                  - - TGATGTCCAC CCGGGTCTAT TTGCCAACTG GTTCACGGGT GGATTGAACT AT -             #CAGATCGA   1260                                                                  - - GCACCACTTG TTCCCTTCGA TGCCTCGCCA CAACTTTTCA AAGATCCAGC CT -             #GCTGTCGA   1320                                                                  - - GACCCTGTGC AAAAAGTACA ATGTCCGATA CCACACCACC GGTATGATCG AG -             #GGAACTGC   1380                                                                  - - AGAGGTCTTT AGCCGTCTGA ACGAGGTCTC CAAGGCTGCC TCCAAGATGG GT -             #AAGGCGCA   1440                                                                  - - GTAAAAAAAA AAACAAGGAC GTTTTTTTTC GCCAGTGCCT GTGCCTGTGC CT -             #GCTTCCCT   1500                                                                  - - TGTCAAGTCG AGCGTTTCTG GAAAGGATCG TTCAGTGCAG TATCATCATT CT -             #CCTTTTAC   1560                                                                  - - CCCCCGCTCA TATCTCATTC ATTTCTCTTA TTAAACAACT TGTTCCCCCC TT - #CACCG           1617                                                                        - -  - - (2) INFORMATION FOR SEQ ID NO:2:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 457 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                - - Met Ala Ala Ala Pro Ser Val Arg Thr Phe Th - #r Arg Ala Glu Val Leu        1               5  - #                 10 - #                 15               - - Asn Ala Glu Ala Leu Asn Glu Gly Lys Lys As - #p Ala Glu Ala Pro Phe                   20      - #            25      - #            30                    - - Leu Met Ile Ile Asp Asn Lys Val Tyr Asp Va - #l Arg Glu Phe Val Pro               35          - #        40          - #        45                        - - Asp His Pro Gly Gly Ser Val Ile Leu Thr Hi - #s Val Gly Lys Asp Gly           50              - #    55              - #    60                            - - Thr Asp Val Phe Asp Thr Phe His Pro Glu Al - #a Ala Trp Glu Thr Leu       65                  - #70                  - #75                  - #80         - - Ala Asn Phe Tyr Val Gly Asp Ile Asp Glu Se - #r Asp Arg Asp Ile Lys                       85  - #                90  - #                95                - - Asn Asp Asp Phe Ala Ala Glu Val Arg Lys Le - #u Arg Thr Leu Phe Gln                   100      - #           105      - #           110                   - - Ser Leu Gly Tyr Tyr Asp Ser Ser Lys Ala Ty - #r Tyr Ala Phe Lys Val               115          - #       120          - #       125                       - - Ser Phe Asn Leu Cys Ile Trp Gly Leu Ser Th - #r Val Ile Val Ala Lys           130              - #   135              - #   140                           - - Trp Gly Gln Thr Ser Thr Leu Ala Asn Val Le - #u Ser Ala Ala Leu Leu       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Gly Leu Phe Trp Gln Gln Cys Gly Trp Leu Al - #a His Asp Phe Leu         His                                                                                              165  - #               170  - #               175              - - His Gln Val Phe Gln Asp Arg Phe Trp Gly As - #p Leu Phe Gly Ala Phe                   180      - #           185      - #           190                   - - Leu Gly Gly Val Cys Gln Gly Phe Ser Ser Se - #r Trp Trp Lys Asp Lys               195          - #       200          - #       205                       - - His Asn Thr His His Ala Ala Pro Asn Val Hi - #s Gly Glu Asp Pro Asp           210              - #   215              - #   220                           - - Ile Asp Thr His Pro Leu Leu Thr Trp Ser Gl - #u His Ala Leu Glu Met       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Phe Ser Asp Val Pro Asp Glu Glu Leu Thr Ar - #g Met Trp Ser Arg         Phe                                                                                              245  - #               250  - #               255              - - Met Val Leu Asn Gln Thr Trp Phe Tyr Phe Pr - #o Ile Leu Ser Phe Ala                   260      - #           265      - #           270                   - - Arg Leu Ser Trp Cys Leu Gln Ser Ile Leu Ph - #e Val Leu Pro Asn Gly               275          - #       280          - #       285                       - - Gln Ala His Lys Pro Ser Gly Ala Arg Val Pr - #o Ile Ser Leu Val Glu           290              - #   295              - #   300                           - - Gln Leu Ser Leu Ala Met His Trp Thr Trp Ty - #r Leu Ala Thr Met Phe       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Leu Phe Ile Lys Asp Pro Val Asn Met Leu Va - #l Tyr Phe Leu Val         Ser                                                                                              325  - #               330  - #               335              - - Gln Ala Val Cys Gly Asn Leu Leu Ala Ile Va - #l Phe Ser Leu Asn His                   340      - #           345      - #           350                   - - Asn Gly Met Pro Val Ile Ser Lys Glu Glu Al - #a Val Asp Met Asp Phe               355          - #       360          - #       365                       - - Phe Thr Lys Gln Ile Ile Thr Gly Arg Asp Va - #l His Pro Gly Leu Phe           370              - #   375              - #   380                           - - Ala Asn Trp Phe Thr Gly Gly Leu Asn Tyr Gl - #n Ile Glu His His Leu       385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - Phe Pro Ser Met Pro Arg His Asn Phe Ser Ly - #s Ile Gln Pro Ala         Val                                                                                              405  - #               410  - #               415              - - Glu Thr Leu Cys Lys Lys Tyr Asn Val Arg Ty - #r His Thr Thr Gly Met                   420      - #           425      - #           430                   - - Ile Glu Gly Thr Ala Glu Val Phe Ser Arg Le - #u Asn Glu Val Ser Lys               435          - #       440          - #       445                       - - Ala Ala Ser Lys Met Gly Lys Ala Gln                                           450              - #   455                                                  - -  - - (2) INFORMATION FOR SEQ ID NO:3:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1488 base - #pairs                                                 (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: DNA (genomic)                                      - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                - - GTCCCCTGTC GCTGTCGGCA CACCCCATCC TCCCTCGCTC CCTCTGCGTT TG -              #TCCTTGGC     60                                                                  - - CCACCGTCTC TCCTCCACCC TCCGAGACGA CTGCAACTGT AATCAGGAAC CG -             #ACAAATAC    120                                                                  - - ACGATTTCTT TTTACTCAGC ACCAACTCAA AATCCTCAAC CGCAACCCTT TT -             #TCAGGATG    180                                                                  - - GCACCTCCCA ACACTATCGA TGCCGGTTTG ACCCAGCGTC ATATCAGCAC CT -             #CGGCCCCA    240                                                                  - - AACTCGGCCA AGCCTGCCTT CGAGCGCAAC TACCAGCTCC CCGAGTTCAC CA -             #TCAAGGAG    300                                                                  - - ATCCGAGAGT GCATCCCTGC CCACTGCTTT GAGCGCTCCG GTCTCCGTGG TC -             #TCTGCCAC    360                                                                  - - GTTGCCATCG ATCTGACTTG GGCGTCGCTC TTGTTCCTGG CTGCGACCCA GA -             #TCGACAAG    420                                                                  - - TTTGAGAATC CCTTGATCCG CTATTTGGCC TGGCCTGTTT ACTGGATCAT GC -             #AGGGTATT    480                                                                  - - GTCTGCACCG GTGTCTGGGT GCTGGCTCAC GAGTGTGGTC ATCAGTCCTT CT -             #CGACCTCC    540                                                                  - - AAGACCCTCA ACAACACAGT TGGTTGGATC TTGCACTCGA TGCTCTTGGT CC -             #CCTACCAC    600                                                                  - - TCCTGGAGAA TCTCGCACTC GAAGCACCAC AAGGCCACTG GCCATATGAC CA -             #AGGACCAG    660                                                                  - - GTCTTTGTGC CCAAGACCCG CTCCCAGGTT GGCTTGCCTC CCAAGGAGAA CG -             #CTGCTGCT    720                                                                  - - GCCGTTCAGG AGGAGGACAT GTCCGTGCAC CTGGATGAGG AGGCTCCCAT TG -             #TGACTTTG    780                                                                  - - TTCTGGATGG TGATCCAGTT CTTGTTCGGA TGGCCCGCGT ACCTGATTAT GA -             #ACGCCTCT    840                                                                  - - GGCCAAGACT ACGGCCGCTG GACCTCGCAC TTCCACACGT ACTCGCCCAT CT -             #TTGAGCCC    900                                                                  - - CGCAACTTTT TCGACATTAT TATCTCGGAC CTCGGTGTGT TGGCTGCCCT CG -             #GTGCCCTG    960                                                                  - - ATCTATGCCT CCATGCAGTT GTCGCTCTTG ACCGTCACCA AGTACTATAT TG -             #TCCCCTAC   1020                                                                  - - CTCTTTGTCA ACTTTTGGTT GGTCCTGATC ACCTTCTTGC AGCACACCGA TC -             #CCAAGCTG   1080                                                                  - - CCCCATTACC GCGAGGGTGC CTGGAATTTC CAGCGTGGAG CTCTTTGCAC CG -             #TTGACCGC   1140                                                                  - - TCGTTTGGCA AGTTCTTGGA CCATATGTTC CACGGCATTG TCCACACCCA TG -             #TGGCCCAT   1200                                                                  - - CACTTGTTCT CGCAAATGCC GTTCTACCAT GCTGAGGAAG CTACCTATCA TC -             #TCAAGAAA   1260                                                                  - - CTGCTGGGAG AGTACTATGT GTACGACCCA TCCCCGATCG TCGTTGCGGT CT -             #GGAGGTCG   1320                                                                  - - TTCCGTGAGT GCCGATTCGT GGAGGATCAG GGAGACGTGG TCTTTTTCAA GA -             #AGTAAAAA   1380                                                                  - - AAAAGACAAT GGACCACACA CAACCTTGTC TCTACAGACC TACGTATCAT GT -             #AGCCATAC   1440                                                                  - - CACTTCATAA AAGAACATGA GCTCTAGAGG CGTGTCATTC GCGCCTCC  - #                   1488                                                                         - -  - - (2) INFORMATION FOR SEQ ID NO:4:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 399 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:                                - - Met Ala Pro Pro Asn Thr Ile Asp Ala Gly Le - #u Thr Gln Arg His Ile       1               5   - #                10  - #                15                - - Ser Thr Ser Ala Pro Asn Ser Ala Lys Pro Al - #a Phe Glu Arg Asn Tyr                   20      - #            25      - #            30                    - - Gln Leu Pro Glu Phe Thr Ile Lys Glu Ile Ar - #g Glu Cys Ile Pro Ala               35          - #        40          - #        45                        - - His Cys Phe Glu Arg Ser Gly Leu Arg Gly Le - #u Cys His Val Ala Ile           50              - #    55              - #    60                            - - Asp Leu Thr Trp Ala Ser Leu Leu Phe Leu Al - #a Ala Thr Gln Ile Asp       65                  - #70                  - #75                  - #80         - - Lys Phe Glu Asn Pro Leu Ile Arg Tyr Leu Al - #a Trp Pro Val Tyr Trp                       85  - #                90  - #                95                - - Ile Met Gln Gly Ile Val Cys Thr Gly Val Tr - #p Val Leu Ala His Glu                   100      - #           105      - #           110                   - - Cys Gly His Gln Ser Phe Ser Thr Ser Lys Th - #r Leu Asn Asn Thr Val               115          - #       120          - #       125                       - - Gly Trp Ile Leu His Ser Met Leu Leu Val Pr - #o Tyr His Ser Trp Arg           130              - #   135              - #   140                           - - Ile Ser His Ser Lys His His Lys Ala Thr Gl - #y His Met Thr Lys Asp       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Gln Val Phe Val Pro Lys Thr Arg Ser Gln Va - #l Gly Leu Pro Pro         Lys                                                                                              165  - #               170  - #               175              - - Glu Asn Ala Ala Ala Ala Val Gln Glu Glu As - #p Met Ser Val His Leu                   180      - #           185      - #           190                   - - Asp Glu Glu Ala Pro Ile Val Thr Leu Phe Tr - #p Met Val Ile Gln Phe               195          - #       200          - #       205                       - - Leu Phe Gly Trp Pro Ala Tyr Leu Ile Met As - #n Ala Ser Gly Gln Asp           210              - #   215              - #   220                           - - Tyr Gly Arg Trp Thr Ser His Phe His Thr Ty - #r Ser Pro Ile Phe Glu       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Pro Arg Asn Phe Phe Asp Ile Ile Ile Ser As - #p Leu Gly Val Leu         Ala                                                                                              245  - #               250  - #               255              - - Ala Leu Gly Ala Leu Ile Tyr Ala Ser Met Gl - #n Leu Ser Leu Leu Thr                   260      - #           265      - #           270                   - - Val Thr Lys Tyr Tyr Ile Val Pro Tyr Leu Ph - #e Val Asn Phe Trp Leu               275          - #       280          - #       285                       - - Val Leu Ile Thr Phe Leu Gln His Thr Asp Pr - #o Lys Leu Pro His Tyr           290              - #   295              - #   300                           - - Arg Glu Gly Ala Trp Asn Phe Gln Arg Gly Al - #a Leu Cys Thr Val Asp       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Arg Ser Phe Gly Lys Phe Leu Asp His Met Ph - #e His Gly Ile Val         His                                                                                              325  - #               330  - #               335              - - Thr His Val Ala His His Leu Phe Ser Gln Me - #t Pro Phe Tyr His Ala                   340      - #           345      - #           350                   - - Glu Glu Ala Thr Tyr His Leu Lys Lys Leu Le - #u Gly Glu Tyr Tyr Val               355          - #       360          - #       365                       - - Tyr Asp Pro Ser Pro Ile Val Val Ala Val Tr - #p Arg Ser Phe Arg Glu           370              - #   375              - #   380                           - - Cys Arg Phe Val Glu Asp Gln Gly Asp Val Va - #l Phe Phe Lys Lys           385                 3 - #90                 3 - #95                             - -  - - (2) INFORMATION FOR SEQ ID NO:5:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 355 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:                                - - Glu Val Arg Lys Leu Arg Thr Leu Phe Gln Se - #r Leu Gly Tyr Tyr Asp       1               5   - #                10  - #                15                - - Ser Ser Lys Ala Tyr Tyr Ala Phe Lys Val Se - #r Phe Asn Leu Cys Ile                   20      - #            25      - #            30                    - - Trp Gly Leu Ser Thr Val Ile Val Ala Lys Tr - #p Gly Gln Thr Ser Thr               35          - #        40          - #        45                        - - Leu Ala Asn Val Leu Ser Ala Ala Leu Leu Gl - #y Leu Phe Trp Gln Gln           50              - #    55              - #    60                            - - Cys Gly Trp Leu Ala His Asp Phe Leu His Hi - #s Gln Val Phe Gln Asp       65                  - #70                  - #75                  - #80         - - Arg Phe Trp Gly Asp Leu Phe Gly Ala Phe Le - #u Gly Gly Val Cys Gln                       85  - #                90  - #                95                - - Gly Phe Ser Ser Ser Trp Trp Lys Asp Lys Hi - #s Asn Thr His His Ala                   100      - #           105      - #           110                   - - Ala Pro Asn Val His Gly Glu Asp Pro Asp Il - #e Asp Thr His Pro Leu               115          - #       120          - #       125                       - - Leu Thr Trp Ser Glu His Ala Leu Glu Met Ph - #e Ser Asp Val Pro Asp           130              - #   135              - #   140                           - - Glu Glu Leu Thr Arg Met Trp Ser Arg Phe Me - #t Val Leu Asn Gln Thr       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Trp Phe Tyr Phe Pro Ile Leu Ser Phe Ala Ar - #g Leu Ser Trp Cys         Leu                                                                                              165  - #               170  - #               175              - - Gln Ser Ile Leu Phe Val Leu Pro Asn Gly Gl - #n Ala His Lys Pro Ser                   180      - #           185      - #           190                   - - Gly Ala Arg Val Pro Ile Ser Leu Val Glu Gl - #n Leu Ser Leu Ala Met               195          - #       200          - #       205                       - - His Trp Thr Trp Tyr Leu Ala Thr Met Phe Le - #u Phe Ile Lys Asp Pro           210              - #   215              - #   220                           - - Val Asn Met Leu Val Tyr Phe Leu Val Ser Gl - #n Ala Val Cys Gly Asn       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Leu Leu Ala Ile Val Phe Ser Leu Asn His As - #n Gly Met Pro Val         Ile                                                                                              245  - #               250  - #               255              - - Ser Lys Glu Glu Ala Val Asp Met Asp Phe Ph - #e Thr Lys Gln Ile Ile                   260      - #           265      - #           270                   - - Thr Gly Arg Asp Val His Pro Gly Leu Phe Al - #a Asn Trp Phe Thr Gly               275          - #       280          - #       285                       - - Gly Leu Asn Tyr Gln Ile Glu His His Leu Ph - #e Pro Ser Met Pro Arg           290              - #   295              - #   300                           - - His Asn Phe Ser Lys Ile Gln Pro Ala Val Gl - #u Thr Leu Cys Lys Lys       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Tyr Asn Val Arg Tyr His Thr Thr Gly Met Il - #e Glu Gly Thr Ala         Glu                                                                                              325  - #               330  - #               335              - - Val Phe Ser Arg Leu Asn Glu Val Ser Lys Al - #a Ala Ser Lys Met Gly                   340      - #           345      - #           350                   - - Lys Ala Gln                                                                       355                                                                     - -  - - (2) INFORMATION FOR SEQ ID NO:6:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 104 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:                                - - Val Thr Leu Tyr Thr Leu Ala Phe Val Ala Al - #a Asn Ser Leu Gly Val       1               5   - #                10  - #                15                - - Leu Tyr Gly Val Leu Ala Cys Pro Ser Val Xa - #a Pro His Gln Ile Ala                   20      - #            25      - #            30                    - - Ala Gly Leu Leu Gly Leu Leu Trp Ile Gln Se - #r Ala Tyr Ile Gly Xaa               35          - #        40          - #        45                        - - Asp Ser Gly His Tyr Val Ile Met Ser Asn Ly - #s Ser Asn Asn Xaa Phe           50              - #    55              - #    60                            - - Ala Gln Leu Leu Ser Gly Asn Cys Leu Thr Gl - #y Ile Ile Ala Trp Trp       65                  - #70                  - #75                  - #80         - - Lys Trp Thr His Asn Ala His His Leu Ala Cy - #s Asn Ser Leu Asp Tyr                       85  - #                90  - #                95                - - Gly Pro Asn Leu Gln His Ile Pro                                                       100                                                                 - -  - - (2) INFORMATION FOR SEQ ID NO:7:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 252 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:                                - - Gly Val Leu Tyr Gly Val Leu Ala Cys Thr Se - #r Val Phe Ala His Gln       1               5   - #                10  - #                15                - - Ile Ala Ala Ala Leu Leu Gly Leu Leu Trp Il - #e Gln Ser Ala Tyr Ile                   20      - #            25      - #            30                    - - Gly His Asp Ser Gly His Tyr Val Ile Met Se - #r Asn Lys Ser Tyr Asn               35          - #        40          - #        45                        - - Arg Phe Ala Gln Leu Leu Ser Gly Asn Cys Le - #u Thr Gly Ile Ser Ile           50              - #    55              - #    60                            - - Ala Trp Trp Lys Trp Thr His Asn Ala His Hi - #s Leu Ala Cys Asn Ser       65                  - #70                  - #75                  - #80         - - Leu Asp Tyr Asp Pro Asp Leu Gln His Ile Pr - #o Val Phe Ala Val Ser                       85  - #                90  - #                95                - - Thr Lys Phe Phe Ser Ser Leu Thr Ser Arg Ph - #e Tyr Asp Arg Lys Leu                   100      - #           105      - #           110                   - - Thr Phe Gly Pro Val Ala Arg Phe Leu Val Se - #r Tyr Gln His Phe Thr               115          - #       120          - #       125                       - - Tyr Tyr Pro Val Asn Cys Phe Gly Arg Ile As - #n Leu Phe Ile Gln Thr           130              - #   135              - #   140                           - - Phe Leu Leu Leu Phe Ser Lys Arg Glu Val Pr - #o Asp Arg Ala Leu Asn       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Phe Ala Gly Ile Leu Val Phe Trp Thr Trp Ph - #e Pro Leu Leu Val         Ser                                                                                              165  - #               170  - #               175              - - Cys Leu Pro Asn Trp Pro Glu Arg Phe Phe Ph - #e Val Phe Thr Ser Phe                   180      - #           185      - #           190                   - - Thr Val Thr Ala Leu Gln His Ile Gln Phe Th - #r Leu Asn His Phe Ala               195          - #       200          - #       205                       - - Ala Asp Val Tyr Val Gly Pro Pro Thr Gly Se - #r Asp Trp Phe Glu Lys           210              - #   215              - #   220                           - - Gln Ala Ala Gly Thr Ile Asp Ile Ser Cys Ar - #g Ser Tyr Met Asp Trp       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Phe Phe Gly Gly Leu Gln Phe Gln Leu Glu Hi - #s His                                       245  - #               250                                      - -  - - (2) INFORMATION FOR SEQ ID NO:8:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 125 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:                                - - Gly Xaa Xaa Asn Phe Ala Gly Ile Leu Val Ph - #e Trp Thr Trp Phe         Pro                                                                              1               5   - #                10  - #                15               - - Leu Leu Val Ser Cys Leu Pro Asn Trp Pro Gl - #u Arg Phe Xaa Phe Val                   20      - #            25      - #            30                    - - Phe Thr Gly Phe Thr Val Thr Ala Leu Gln Hi - #s Ile Gln Phe Thr Leu               35          - #        40          - #        45                        - - Asn His Phe Ala Ala Asp Val Tyr Val Gly Pr - #o Pro Thr Gly Ser Asp           50              - #    55              - #    60                            - - Trp Phe Glu Lys Gln Ala Ala Gly Thr Ile As - #p Ile Ser Cys Arg Ser       65                  - #70                  - #75                  - #80         - - Tyr Met Asp Trp Phe Phe Cys Gly Leu Gln Ph - #e Gln Leu Glu His His                       85  - #                90  - #                95                - - Leu Phe Pro Arg Leu Pro Arg Cys His Leu Ar - #g Lys Val Ser Pro Val                   100      - #           105      - #           110                   - - Gly Gln Arg Gly Phe Gln Arg Lys Xaa Asn Le - #u Ser Xaa                           115          - #       120          - #       125                       - -  - - (2) INFORMATION FOR SEQ ID NO:9:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 131 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:                                - - Pro Ala Thr Glu Val Gly Gly Leu Ala Trp Me - #t Ile Thr Phe Tyr Val       1               5   - #                10  - #                15                - - Arg Phe Phe Leu Thr Tyr Val Pro Leu Leu Gl - #y Leu Lys Ala Phe Leu                   20      - #            25      - #            30                    - - Gly Leu Phe Phe Ile Val Arg Phe Leu Glu Se - #r Asn Trp Phe Val Trp               35          - #        40          - #        45                        - - Val Thr Gln Met Asn His Ile Pro Met His Il - #e Asp His Asp Arg Asn           50              - #    55              - #    60                            - - Met Asp Trp Val Ser Thr Gln Leu Gln Ala Th - #r Cys Asn Val His Lys       65                  - #70                  - #75                  - #80         - - Ser Ala Phe Asn Asp Trp Phe Ser Gly His Le - #u Asn Phe Gln Ile Glu                       85  - #                90  - #                95                - - His His Leu Phe Pro Thr Met Pro Arg His As - #n Tyr His Xaa Val Ala                   100      - #           105      - #           110                   - - Pro Leu Val Gln Ser Leu Cys Ala Lys His Gl - #y Ile Glu Tyr Gln Ser               115          - #       120          - #       125                       - - Lys Pro Leu                                                                   130                                                                         - -  - - (2) INFORMATION FOR SEQ ID NO:10:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 87 amino - #acids                                                  (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:                               - - Cys Ser Pro Lys Ser Ser Pro Thr Arg Asn Me - #t Thr Pro Ser Pro Phe       1               5   - #                10  - #                15                - - Ile Asp Trp Leu Trp Gly Gly Leu Asn Tyr Gl - #n Ile Glu His His Leu                   20      - #            25      - #            30                    - - Phe Pro Thr Met Pro Arg Cys Asn Leu Asn Ar - #g Cys Met Lys Tyr Val               35          - #        40          - #        45                        - - Lys Glu Trp Cys Ala Glu Asn Asn Leu Pro Ty - #r Leu Val Asp Asp Tyr           50              - #    55              - #    60                            - - Phe Val Gly Tyr Asn Leu Asn Leu Gln Gln Le - #u Lys Asn Met Ala Glu       65                  - #70                  - #75                  - #80         - - Leu Val Gln Ala Lys Ala Ala                                                               85                                                              - -  - - (2) INFORMATION FOR SEQ ID NO:11:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 143 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: Not R - #elevant                                             (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: peptide                                            - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:                               - - Arg His Glu Ala Ala Arg Gly Gly Thr Arg Le - #u Ala Tyr Met Leu Val       1               5   - #                10  - #                15                - - Cys Met Gln Trp Thr Asp Leu Leu Trp Ala Al - #a Ser Phe Tyr Ser Arg                   20      - #            25      - #            30                    - - Phe Phe Leu Ser Tyr Ser Pro Phe Tyr Gly Al - #a Thr Gly Thr Leu Leu               35          - #        40          - #        45                        - - Leu Phe Val Ala Val Arg Val Leu Glu Ser Hi - #s Trp Phe Val Trp Ile           50              - #    55              - #    60                            - - Thr Gln Met Asn His Ile Pro Lys Glu Ile Gl - #y His Glu Lys His Arg       65                  - #70                  - #75                  - #80         - - Asp Trp Ala Ser Ser Gln Leu Ala Ala Thr Cy - #s Asn Val Glu Pro Ser                       85  - #                90  - #                95                - - Leu Phe Ile Asp Trp Phe Ser Gly His Leu As - #n Phe Gln Ile Glu His                   100      - #           105      - #           110                   - - His Leu Phe Pro Thr Met Thr Arg His Asn Ty - #r Arg Xaa Val Ala Pro               115          - #       120          - #       125                       - - Leu Val Lys Ala Phe Cys Ala Lys His Gly Le - #u His Tyr Glu Val              130               - #  135               - #  140                            - -  - - (2) INFORMATION FOR SEQ ID NO:12:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 35 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:                               - - CCAAGCTTCT GCAGGAGCTC TTTTTTTTTT TTTTT       - #                  -      #       35                                                                       - -  - - (2) INFORMATION FOR SEQ ID NO:13:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 33 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:                               - - CUACUACUAC UAGGAGTCCT CTACGGTGTT TTG       - #                  - #              33                                                                       - -  - - (2) INFORMATION FOR SEQ ID NO:14:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 33 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:                               - - CAUCAUCAUC AUATGATGCT CAAGCTGAAA CTG       - #                  - #              33                                                                       - -  - - (2) INFORMATION FOR SEQ ID NO:15:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 39 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:                               - - TACCAACTCG AGAAAATGGC TGCTGCTCCC AGTGTGAGG      - #                       - #    39                                                                       - -  - - (2) INFORMATION FOR SEQ ID NO:16:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 39 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:                               - - AACTGATCTA GATTACTGCG CCTTACCCAT CTTGGAGGC      - #                       - #    39                                                                       - -  - - (2) INFORMATION FOR SEQ ID NO:17:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 39 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:                               - - TACCAACTCG AGAAAATGGC ACCTCCCAAC ACTATCGAT      - #                       - #    39                                                                       - -  - - (2) INFORMATION FOR SEQ ID NO:18:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 39 base - #pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (ii) MOLECULE TYPE: other nucleic acid                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:                               - - AACTGATCTA GATTACTTCT TGAAAAAGAC CACGTCTCC      - #                       - #    39                                                                     __________________________________________________________________________ 

What is claimed is:
 1. A method for production of γ-linolenic acid in a yeast culture, said method comprising:growing a yeast culture having a plurality of recombinant yeast cells, wherein said yeast cells or an ancestor of said yeast cells were transformed with a vector comprising Mortierella alpina DNA encoding a Δ6 desaturase polypeptide which converts linoleic acid to γ-linolenic acid, wherein said DNA is operably associated with an expression control sequence functional in said yeast cells, under conditions whereby said DNA is expressed, whereby γ-linolenic acid is produced from linoleic acid in said yeast culture.
 2. The method according to claim 1, wherein said linolenic acid is exogenously supplied.
 3. The method according to claim 1 wherein said conditions are inducible.
 4. The method according to claim 1 wherein said fungal DNA comprises the DNA sequence depicted in SEQ ID NO:1.
 5. The method of according to claim 1 wherein said polypeptide comprises the polypeptide sequence depicted in SEQ ID NO:2.
 6. A method for production of stearidonic acid in a yeast culture, said method comprising:growing a yeast culture having a plurality of recombinant yeast cells, wherein said yeast cells or an ancestor of said yeast cells were transformed with a vector comprising Mortierella alpina DNA encoding a Δ6 desaturase polypeptide which converts α-linolenic acid to stearidonic acid, wherein said DNA is operably associated with an expression control sequence functional in said yeast cells, under conditions whereby said DNA is expressed, whereby stearidonic acid is produced from α-linolenic acid in said yeast culture.
 7. The method according to claim 6 wherein said α-linolenic acid is exogenously supplied.
 8. The method according to claim 6 wherein said conditions are inducible.
 9. The method according to claim 6 wherein said Mortierella alpina DNA comprises the DNA sequence depicted in SEQ ID NO:1.
 10. The method according to claim 6 wherein the polypeptide comprises the polypeptide sequence depicted in SEQ ID NO:2.
 11. A method for production of linoleic acid in a yeast culture, said method comprising:growing a yeast culture having a plurality of recombinant yeast cells, wherein said yeast cells or an ancestor of said yeast cells were transformed with a vector comprising Mortierella alpina DNA encoding a Δ12 desaturase polypeptide which converts oleic acid to linoleic acid, wherein said DNA is operably associated with an expression control sequence functional in said yeast cells, under conditions whereby said DNA is expressed, whereby linoleic acid is produced oleic acid in said yeast culture.
 12. The method according to claim 11 wherein said conditions are inducible.
 13. The method according to claim 11 wherein said Mortierella alpina DNA comprises the DNA sequence depicted in SEQ ID NO:3.
 14. The method according to claim 11 wherein the polypeptide comprises the polypeptide sequence depicted in SEQ ID NO:4.
 15. A method for production of stearidonic acid in a eukaryotic cell culture, said method comprising:growing a eukaryotic cell culture having a plurality of recombinant eukaryotic cells, wherein said recombinant eukaryotic cells or ancestors of said recombinant eukaryotic cells were transformed with a vector comprising Mortierella alpina DNA encoding a polypeptide which converts α-linolenic to stearidonic acid, wherein said DNA is operably associated with an expression control sequence functional in said recombinant eukaryotic cells, under conditions whereby said DNA is expressed, whereby stearidonic acid is produced from α-linolenic in said eukaryotic cell culture.
 16. A method for production of linoleic acid in a eukaryotic cell culture, said method comprising:growing a eukaryotic cell culture having a plurality of recombinant eukaryotic cells, wherein said recombinant eukaryotic cells or ancestors of said recombinant eukaryotic cells were transformed with a vector comprising Mortierella alpina DNA encoding a polypeptide which converts oleic acid to linoleic acid, wherein said DNA is operably associated with an expression control sequence functional in said recombinant eukaryotic cells, under conditions whereby said DNA is expressed, whereby linoleic acid is produced from oleic acid in said eukaryotic cell culture.
 17. The method according to claim 15, wherein said eukaryotic cells are selected from the group consisting of mammalian cells, fungal cells, avian cells and algal cells.
 18. The method according to claim 16 wherein said eukaryotic cells are selected from the group of mammalian cells, fungal cells, avian cells and algal cells.
 19. The method according to claim 17, wherein said fungal cells are yeast cells of the genus Saccharomyces.
 20. The method according to claim 18, wherein said fungal cells are yeast cells of the genus Saccharomyces.
 21. A method of making α-linolenic acid, said method comprising:growing a recombinant yeast cell comprising a nucleotide sequence which encodes a functionally active Δ6 desaturase having the amino acid sequence depicted in SEQ ID NO:2, and at least one nucleic acid construct comprising a nucleotide sequence which encodes a functionally active Δ12 desaturase having an amino acid sequence depicted in SEQ ID NO:4, wherein said nucleic acid constructs are operably associated with transcription control sequences functional in a yeast cell under conditions whereby said nucleotide sequences are expressed, whereby γ-linolenic acid is produced in said yeast cell.
 22. The method according to claim 21 wherein said conditions are inducible. 